



STATISTICAL ANALYSIS PLAN

Study Title: A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 weeks in Combination with Methotrexate to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

Name of Test Drug: Filgotinib

Study Number: GS-US-417-0301

Protocol Version (Date): Amendment 1: 05 July 2016

Analysis Type: Week 24 Analysis and Final Analysis

Analysis Plan Version: Version 1.0

Analysis Plan Date: 05 February 2019

Analysis Plan Author(s): Lei Ye, PhD

CONFIDENTIAL AND PROPRIETARY INFORMATION

TABLE OF CONTENTS

TABLE OF CONTENTS	2
LIST OF IN-TEXT TABLES	5
LIST OF IN-TEXT FIGURES	5
LIST OF ABBREVIATIONS.....	6
PHARMACOKINETIC ABBREVIATIONS.....	9
1. INTRODUCTION	10
1.1. Study Objectives	10
1.2. Study Design	11
1.3. Sample Size and Power	12
2. TYPE OF PLANNED ANALYSIS	14
2.1. Data Monitoring Committee Analyses.....	14
2.2. Week 24 Analysis	14
2.3. Final Analysis	14
3. GENERAL CONSIDERATIONS FOR DATA ANALYSES	15
3.1. Analysis Sets	15
3.1.1. All Randomized Analysis Set.....	15
3.1.2. Full Analysis Set	15
3.1.3. Per-Protocol Analysis Set.....	15
3.1.4. Safety Analysis Set.....	17
3.1.5. Pharmacokinetic Analysis Set	17
3.1.6. Pharmacokinetic Substudy Analysis Set	17
3.2. Subject Grouping	17
3.3. Strata and Covariates.....	18
3.4. Examination of Subject Subgroups	18
3.5. Multiple Comparisons	19
3.6. Missing Data and Outliers.....	20
3.6.1. Missing Data	20
3.6.2. Outliers.....	21
3.7. Data Handling Conventions and Transformations	21
3.8. Analysis Visit Windows.....	22
3.8.1. Definition of Study Day	22
3.8.2. Analysis Visit Windows	22
3.8.3. Selection of Non-Efficacy Data in the Event of Multiple Records in an Analysis Visit Window	29
4. SUBJECT DISPOSITION	30
4.1. Subject Enrollment and Disposition.....	30
4.2. Extent of Study Drug Exposure and Adherence.....	31
4.2.1. Duration of Exposure to Study Drug.....	31
4.2.2. Adherence to Study Drug	32
4.3. Protocol Deviations	34
5. BASELINE CHARACTERISTICS	35
5.1. Demographics and Other Baseline Characteristics	35
5.2. Baseline Disease Characteristics	35
5.3. Medical History.....	37

6.	EFFICACY ANALYSES	38
6.1.	General Considerations	38
6.1.1.	Tender/Swollen Joint Counts (TJC/SJC).....	41
6.1.2.	Global Assessment of Disease Activity.....	42
6.1.3.	Health Assessment Questionnaire Disability Index (HAQ-DI).....	43
6.2.	Primary Efficacy Endpoint.....	43
6.2.1.	Definition of the Primary Efficacy Endpoint	43
6.2.2.	Statistical Hypothesis for the Primary Efficacy Endpoint	44
6.2.3.	Primary Analysis of the Primary Efficacy Endpoint	44
6.2.4.	Sensitivity Analysis of the Primary Endpoint	45
6.2.5.	Subgroup Analysis of the Primary Endpoint	46
6.3.	Key Secondary Efficacy Endpoints.....	46
6.3.1.	Definition of Key Secondary Efficacy Endpoints	47
6.3.2.	Analysis Methods for Key Secondary Efficacy Endpoints	48
6.3.3.	Sensitivity Analysis for Key Secondary Efficacy Endpoints	49
6.3.4.	Subgroup Analyses for Key Secondary Efficacy Endpoints	52
6.4.	Other Secondary Efficacy Endpoints	52
6.4.1.	Definition of Other Secondary Efficacy Endpoints.....	53
6.4.2.	Analysis Methods for Other Secondary Efficacy Endpoints	56
6.5.	Changes From Protocol-Specified Efficacy Analyses.....	60
7.	SAFETY ANALYSES.....	61
7.1.	Adverse Events and Deaths.....	61
7.1.1.	Adverse Event Dictionary	61
7.1.2.	Adverse Event Severity	61
7.1.3.	Relationship of Adverse Events to Study Drug.....	61
7.1.4.	Serious Adverse Events.....	61
7.1.5.	Treatment-Emergent Adverse Events.....	61
7.1.6.	Summaries of Adverse Events and Deaths.....	62
7.1.7.	Adverse Events of Special Interest.....	64
7.1.8.	Additional Analysis for Adverse Events	65
7.2.	Laboratory Evaluations	66
7.2.1.	Summaries of Numeric Laboratory Results	66
7.2.2.	Graded Laboratory Value.....	68
7.2.3.	Laboratory Evaluations of Special Interest	70
7.3.	Body Weight and Vital Signs.....	71
7.4.	Prior and Concomitant Medications.....	71
7.4.1.	Prior Medications	72
7.4.2.	Concomitant Medications.....	72
7.5.	Electrocardiogram Results	73
7.5.1.	Investigator Electrocardiogram Assessment	73
7.6.	Other Safety Measures	73
7.7.	Changes From Protocol-Specified Safety Analyses.....	73
8.	PHARMACOKINETIC ANALYSES	74
8.1.	PK Analyses Related to Intensive PK Sampling.....	74
8.1.1.	Estimation of Pharmacokinetic Parameters.....	74
8.1.2.	Pharmacokinetic Parameters	74
8.1.3.	Statistical Analysis Methods	75
9.	BIOMARKER ANALYSIS	77
10.	REFERENCES	78
11.	SOFTWARE	79

12.	SAP REVISION.....	80
13.	APPENDIX.....	81
Appendix 1.	Lists of RA Medications.....	81
Appendix 2.	Health Assessment Questionnaire Disability Index (HAQ-DI).....	83
Appendix 3.	van der Heijde modified Total Sharp Score (mTSS).....	85
Appendix 4.	Treatment Satisfaction Questionnaire for Medication (TSQM).....	88
Appendix 5.	Corticosteroids.....	89
Appendix 6.	SAS Programming for Tipping Point Analysis for Binary Endpoint.....	90
Appendix 7.	SAS Programming for Tipping Point Analysis for Continuous Endpoint.....	92
Appendix 8.	Sample SAS Code for Analysis of Binary Endpoints.....	94

LIST OF IN-TEXT TABLES

Table 3-1.	Analysis Visit Windows for On-Treatment Joint Count Assessment, HAQ-DI, SGA, PGA, CRP, Exploratory PRO, and Vital Signs, Weight, and Safety Laboratory Data (Lipid Data Excluded) for Subjects who were Initially Randomized to Filgotinib or Adalimumab, and Subjects who were Initially Randomized to Placebo and not Re-randomized	24
Table 3-2.	Analysis Visit Windows for On-Treatment Joint Count Assessment, HAQ-DI, SGA, PGA, CRP, Exploratory PRO, and Vital Signs, Weight, and Safety Laboratory Data (Lipid Data Excluded) for Subjects who were Initially Randomized to Placebo and Re-randomized	25
Table 3-3.	Analysis Visit Windows for On-Treatment Lipid Data for Subjects who were Initially Randomized to Filgotinib or Adalimumab, and Subjects who were Initially Randomized to Placebo and not Re-randomized	25
Table 3-4.	Analysis Visit Windows for On-Treatment mTSS for Subjects who were Initially Randomized to Filgotinib or Adalimumab, and Subjects who were Initially Randomized to Placebo and not Re-randomized	26
Table 3-5.	Analysis Visit Windows for On-Treatment Lipid Data for Subjects who were Initially Randomized to Placebo and Re-randomized	26
Table 3-6.	Analysis Visit Windows for On-Treatment mTSS data for Subjects who were Initially Randomized to Placebo and Re-randomized	26
Table 3-7.	Analysis Visit Windows for On-Treatment HRUQ,TSQM and ECG Data for Subjects who were Initially Randomized to Filgotinib or Adalimumab, and Subjects who were Initially Randomized to Placebo and not Re-randomized	27
Table 3-8.	Analysis Visit Windows for On-Treatment HRUQ,TSQM and ECG Data for Subjects who were Initially Randomized to Placebo and Re-randomized	27
Table 3-9.	Analysis Visit Windows for On-Treatment SF-36, FACIT-Fatigue, EQ-5D, and WPAI-RA for Subjects who were Initially Randomized to Filgotinib or Adalimumab, and Subjects who were Initially Randomized to Placebo and not Re-randomized	28
Table 3-10.	Analysis Visit Windows for On-Treatment SF-36, FACIT-Fatigue, EQ-5D, and WPAI-RA for Subjects who were Initially Randomized to Placebo and Re-randomized	28
Table 6-1.	Composition of the 28 Joints	42
Table 6-2.	EULAR Response Criteria	54
Table 8-1.	Study Treatments and Associated Analytes	74
Table 8-2.	Pharmacokinetic Parameters for Each Analyte	75

LIST OF IN-TEXT FIGURES

Figure 1-1.	Study Design	12
-------------	--------------------	----

LIST OF ABBREVIATIONS

Ab	antibody
ACR	American College of Rheumatology
ACR20/50/70	American College of Rheumatology 20/50/70% improvement
AE	adverse event
AESIs	adverse events of special interest
ALP	alkaline phosphatase
ALT	alanine aminotransferase
ANCOVA	analysis of covariance
anti-CCP Ab	anti- Cyclic Citrullinated Peptide Antibody
AST	aspartate aminotransferase
ATC	anatomical therapeutic chemical drug class
bDMARD	biological disease modifying anti-rheumatic drug
BLQ	below the limit of quantitation
BMI	body mass index
CBC	complete blood count
CCP	cyclic citrullinated peptide
CDAI	clinical disease activity index
CI	confidence interval
CPK	creatine phosphokinase
CRF	case report form
CSR	clinical study report
CTCAE	Common Toxicity Criteria for Adverse Events
DAS28	disease activity score for 28 joint count
DMC	data monitoring committee
ECG	electrocardiogram
eCRF	electronic case report form
EQ-5D	EuroQoL 5 Dimensions
ET	early termination
EULAR	European League Against Rheumatism
FACIT-Fatigue	Functional Assessment of Chronic Illness Therapy-Fatigue
FAS	full analysis set
GI	Gastrointestinal
Gilead	Gilead Sciences
HAQ-DI	health assessment questionnaire-disability index
HLGT	high-level group term
HLT	high-level term
HRQoL	health-related quality of life
HRUQ	healthcare resource utilization questionnaire

hsCRP	high-sensitivity C-Reactive Protein
ID	identification
IWRS	interactive web response system
LLOQ	lower limit of quantitation
LLT	lower-level term
LOCF	last observation carried forward
LOQ	limit of quantitation
LS	least squares
LTE	long-term extension
MedDRA	Medical Dictionary for Regulatory Activities
MI	multiple imputation
MMRM	mixed model repeated measures
MNAR	missing not at random
MST	MedDRA search term
mTSS	van der Heijde modified Total Sharp Score
MTX	methotrexate
NRI	non-responder imputation
OC	observed case
PD	pharmacodynamics
PGA	physician's global assessment
PK	pharmacokinetic
PP	per-protocol
PT	preferred term
PTM	placebo to match
PVE	pharmacovigilance & epidemiology department
Q1, Q3	first quartile, third quartile
q.d.	quaque die (each day)
RA	rheumatoid arthritis
RF	rheumatoid factor
SAE	serious adverse event
SAP	statistical analysis plan
SD	standard deviation
SDAI	simplified disease activity index
SDC	smallest detectable change
SE	standard error
SF-36	36-item short form survey
SGA	subject's global assessment
SJC	swollen joint count
SMQ	standardized MedDRA query
SOC	system organ class

TEAE	treatment-emergent adverse event
TFLs	tables, figures, and listings
TNF	tumor necrosis factor-alpha
TJC	tender joint count
TSQM	treatment satisfaction questionnaire for medication
ULN	upper limit of normal
VAS	visual analog scale
VR	ventricular rate
WBC	white blood cell
WHO	World Health Organization
WPAI	Work Productivity and Activity Impairment

PHARMACOKINETIC ABBREVIATIONS

AUC_{last}	area under the concentration versus time curve from time zero to the last quantifiable concentration
AUC_{tau}	area under the concentration versus time curve over the dosing interval
C_{last}	last observed quantifiable concentration of the drug
C_{max}	maximum observed concentration of drug
C_{tau}	observed drug concentration at the end of the dosing interval
CL_{ss}/F	apparent oral clearance after administration of the drug: at steady state: $CL_{ss}/F = Dose/AUC_{tau}$, where “Dose” is the dose of the drug
$t_{1/2}$	estimate of the terminal elimination half-life of the drug, calculated by dividing the natural log of 2 by the terminal elimination rate constant (λ_z)
T_{last}	time (observed time point) of C_{last}
T_{max}	time (observed time point) of C_{max}
V_z/F	apparent volume of distribution of the drug
λ_z	terminal elimination rate constant, estimated by linear regression of the terminal elimination phase of the concentration of drug versus time curve

1. INTRODUCTION

This statistical analysis plan (SAP) describes the statistical analysis methods and data presentations to be used in tables, figures, and listings (TFLs) in the clinical study report (CSR) for Study GS-US-417-0301. This SAP is based on the study protocol Amendment 1 dated 05 July 2016 and the electronic case report form (eCRF). The SAP will be finalized before the unblinding of Week 24 analysis. Any changes made after the finalization of the SAP will be documented in the CSR.

1.1. Study Objectives

The primary objective of this study is as follows:

- To evaluate the effects of filgotinib versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA) as measured by the proportion of subjects achieving an American College of Rheumatology 20% improvement response (ACR20) at Week 12

The secondary objectives of this study are as follows:

- To evaluate the effects of filgotinib versus placebo as measured by the proportion of subjects achieving Disease Activity Score for 28 joint count using c-reactive protein (DAS28[CRP]) 3.2 at Week 12
- To evaluate the effect of filgotinib versus placebo on physical function as measured by change from Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) score at Week 12
- To evaluate the effects of filgotinib versus placebo for the treatment of signs and symptoms of RA as measured by the proportion of subjects achieving DAS28(CRP) < 2.6 at Week 24
- To evaluate the effects of filgotinib versus placebo on preservation of joint structure as measured by change from Baseline in van der Heijde modified Total Sharp Score (mTSS) at Week 24
- To evaluate the effects of filgotinib versus adalimumab for the treatment of signs and symptoms of RA as measured by the proportion of subjects achieving DAS28(CRP) 3.2 at Week 12
- To evaluate the safety and tolerability of filgotinib
- To evaluate the effects of filgotinib on work productivity, fatigue, and general quality of life as measured by 36-Item Short Form Survey (SF-36), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue), EuroQol 5 Dimensions (EQ-5D) and Work Productivity and Activity Impairment-Rheumatoid Arthritis (WPAI-RA)

The exploratory objectives of this study are as follows:

- To characterize the pharmacokinetics (PK) of filgotinib and its metabolite (GS-829845, formerly G254445)
- To characterize the association of host genetics and other markers with disease severity, disease progression and treatment response to filgotinib in subjects with RA
- To evaluate the effects of filgotinib on healthcare resource utilization and other patient reported outcomes

1.2. Study Design

This is a randomized, double-blind, placebo- and active-controlled, Phase 3 study in adult male and female subjects with active RA who have an inadequate response to MTX (MTX-IR). The study is designed to evaluate the efficacy, safety, and tolerability of filgotinib as well as its effect on work productivity, fatigue, and quality of life.

Approximately 1650 subjects will be randomized in a 3:3:2:3 ratio to filgotinib 200 mg, filgotinib 100 mg, active comparator (adalimumab), or placebo to match (PTM) administered for up to 52 weeks, all in the context of a weekly stable dose of MTX:

- Filgotinib 200 mg group: filgotinib (200 mg q.d.) + PTM filgotinib 100 mg (PTM q.d.) + PTM adalimumab (PTM s.c. injection q2w) (N=450)
- Filgotinib 100 mg group: filgotinib (100 mg q.d.) + PTM filgotinib 200 mg (PTM q.d.) + PTM adalimumab (PTM s.c. injection q2w) (N=450)
- Active comparator group: PTM filgotinib 200 mg (PTM q.d.) + PTM filgotinib 100 mg (PTM q.d.) + adalimumab (40 mg s.c. injection q2w) (N=300)
- Placebo control group: PTM filgotinib 200 mg (PTM q.d.) + PTM filgotinib 100 mg (PTM q.d.) + PTM adalimumab (PTM s.c. injection q2w) (N=450)

Randomization will be stratified by geographic region, prior exposure to biologic disease modifying antirheumatic drugs (bDMARDs), and presence of rheumatoid factor (RF) or anti-CCP (cyclic citrullinated peptide) antibody (Ab) at screening.

At Week 14, subjects who have not achieved at least 20% improvement from Baseline in both swollen joint count (SJC) and tender joint count (TJC) will discontinue investigational study drug dosing but will continue with study visits and assessments per protocol. All subjects meeting this criterion who discontinue from investigational therapy are to receive standard of care treatment for their RA as determined by the investigator.


At Week 24, all subjects assigned to placebo + MTX will be reassigned 1:1 to either filgotinib 100 mg q.d. or 200 mg q.d. in addition to MTX in a blinded fashion and will continue in the study per protocol up to Week 52.

All subjects who continue on study drug will be evaluated for loss of therapeutic response from Week 30 through Week 52. Subjects failing to maintain at least a 20% improvement from Baseline in TJC and SJC, (which is confirmed at 2 consecutive visits), will discontinue from investigational study drug therapy but will continue with study visits and assessments per protocol. All subjects meeting this criterion who discontinue from investigational study drug dosing are to receive standard of care treatment for their RA as determined by the investigator.

All subjects who have received at least one dose of study drug and exit the study early will complete an early termination (ET) visit at the time of study discontinuation, with a follow up visit four weeks after the last dose of study drug (Post Treatment Week 4), regardless of dosing duration.

At completion of the 52-week dosing period, subjects who have not discontinued assigned study drug dosing, will be provided the option to enroll into a separate Long Term Extension (LTE) study (GS-US-417-0304).

Figure 1-1. Study Design



1.3. Sample Size and Power

Sample size is determined based on the superiority test of filgotinib 200 mg compared to placebo based on the change from Baseline in mTSS at Week 24. When assuming a difference of 0.4 between filgotinib and placebo on change from Baseline in mTSS at Week 24 and a common standard deviation of 1.85, 450 subjects in each of the filgotinib 200 mg group and placebo control group are required to obtain 90% power at a 2-sided 0.05-level.

A sample size of 450 subjects in each of the filgotinib groups and placebo control group will provide over 95% power to detect an increase in ACR20 response rate of 45% to 65% between the placebo control group and the filgotinib group respectively, using a 2-sided 0.05-level test.

Based on {[Liu 2014](#)}, 450 subjects in each of the filgotinib 200 mg group and placebo group, and 300 subjects in the adalimumab group, will provide over 90% power at 2-sided 0.05 significance level to demonstrate that filgotinib 200 mg preserves more than 50% of the effect of adalimumab with respect to the response rate of DAS28(CRP) 3.2 at Week 12, assuming both filgotinib 200 mg and adalimumab groups have similar response rates of DAS28(CRP) 3.2. Given this study has a placebo group, assay sensitivity can be established through a direct comparison of adalimumab to placebo.

In summary, the total planned sample size will be 1650 (450 for the filgotinib 200 mg, filgotinib 100 mg, placebo groups, and 300 for the active comparator group).

2. TYPE OF PLANNED ANALYSIS

2.1. Data Monitoring Committee Analyses

An external multidisciplinary Data Monitoring Committee (DMC) will review the progress of the study and perform interim reviews of safety data in order to protect subject welfare and preserve study integrity. To ensure the best interests of the participants, the DMC will recommend to the sponsor if the nature, frequency, and severity of adverse effects associated with the study treatment warrant the early termination of the study, the continuation of the study, or the continuation of the study with modifications.

The initial review has been conducted after approximately 100 subjects have completed at least 12 weeks of dosing in any one of the three RA phase 3 studies (GS-US-417-0301, GS-US-417-0302, and GS-US-417-0303). Regular DMC review of safety data will be scheduled approximately every 6 months following the initial data review meeting including all 3 RA phase 3 studies and a long-term extension study (GS-US-417-0304).

The DMC's role and responsibilities and the scope of analysis to be provided to the DMC are provided in a mutually agreed upon charter, which defines the DMC membership, meeting logistics, and meeting frequency.

2.2. Week 24 Analysis

A planned Week 24 analysis will be conducted after all subjects have either completed their Week 24 visit or prematurely discontinued from the study. A pre-specified sponsor team including members of which are not actively involved in the conduct of the study, will review the Week 24 unblinded safety and efficacy analysis results. A memo and a list will be maintained which documents the individuals who have been granted access to the Week 24 unblinded results along with the justification for unblinding in accordance with Gilead SOPs. A data integrity and communication plan for the pre-specified Week 24 analysis will be finalized prior to unblinding. The Study Management Team members with direct involvement in the conduct of the study will either be replaced if they need to be unblinded, or remain blinded to treatment assignments throughout the trial, until all subjects have completed the planned study Week 52 visits and the database has been locked.

2.3. Final Analysis

After all subjects have completed the study, outstanding data queries have been resolved or adjudicated as unresolvable, and the data have been cleaned and finalized, the study blind will be broken and the final analysis of the data will be performed.

3. GENERAL CONSIDERATIONS FOR DATA ANALYSES

Analysis results will be presented using descriptive statistics. For categorical variables, the number and percentage of subjects in each category will be presented; for continuous variables, the number of subjects (n), mean, standard deviation (SD) or standard error (SE), median, first quartile (Q1), third quartile (Q3), minimum, and maximum will be presented.

All statistical tests will be 2-sided and performed at the 5% significance level unless otherwise specified.

By-subject listings will be presented for all subjects in the All Randomized Analysis Set and sorted by subject identification (ID) number, visit date, and time (if applicable). Data collected on log forms, such as AEs, will be presented in chronological order within the subject. The treatment group to which subjects were randomized will be included in the listings, as well as age, sex at birth, race, and ethnicity.

3.1. Analysis Sets

Analysis sets define the subjects to be included in an analysis. Analysis sets and their definitions are provided in this section. Subjects included in each analysis set will be determined before the study blind is broken for analysis. The analysis set will be identified and included as a subtitle of each TFL.

For each analysis set, the number and percentage of subjects eligible for inclusion, as well as the number and percentage of subjects who were excluded and the reasons for their exclusion, will be summarized by treatment group.

A listing of reasons for exclusion from analysis sets will be provided by subject.

3.1.1. All Randomized Analysis Set

All Randomized Analysis Set includes all subjects who are randomized in the study. This is the primary analysis set for by-subject listings.

3.1.2. Full Analysis Set

The Full Analysis Set (FAS) includes all randomized subjects who received at least 1 dose of study drug. The study drugs in this study are filgotinib 200 mg, filgotinib 100 mg, adalimumab and PTMs. This is the primary analysis set for efficacy analyses.

3.1.3. Per-Protocol Analysis Set

The Per-Protocol (PP) Analysis Set includes subjects in the FAS who did not have major protocol deviations occurring prior to or on Week 12 that will affect the efficacy analysis, and were compliant (with on-treatment adherence ≥ 80% in the first 12-week period) to study treatment.

Major protocol deviations include the following:

- Violation of at least one of the following key eligibility criteria:
 - 1) Have a diagnosis of RA (2010 ACR/EULAR criteria for RA), and are ACR functional class I-III
 - 2) Have 6 swollen joints (from swollen joint count based on 66 joints [SJC66]) and 6 tender joints (from tender joint count based on 68 joints [TJC68]) at both Screening and Day 1 (need not be the same joints)
 - 3) Must meet at least one of the following parameters at Screening:
 - a) 1 documented joint erosion on radiographs of the hands, wrists or feet by central reading AND a positive result for anti-CCP or RF (based on central laboratory)OR
 - b) 3 documented erosions on radiographs of the hands, wrists or feet by central reading if both antibodies (ie, RF, anti-CCP) are negative (based on central laboratory)OR
 - c) Serum CRP 6 mg/L (based on central laboratory)
 - 4) Ongoing treatment with a stable dose of MTX as described in protocol
 - 5) Subjects that have failed prior therapy with a bDMARD are not eligible to participate. Subjects with prior exposure to one bDMARD may be enrolled if there is documented evidence of limited exposure (ie, less than 3 months) to the bDMARD
- Received prohibited concomitant medications
- Background medications were changed in violation of protocol
- Improper study medication administration and unintended medication overdose
- Data were questionable because of significant site quality or compliance issues

Qualifications and identification of the specific major protocol deviations that result in exclusion from the PP Analysis Set will be determined while the study remains blinded, prior to database finalization.

The PP Analysis Set is the secondary analysis set for efficacy analyses on primary and key secondary endpoints at Week 12. Statistical analyses using PP Analysis Set are specified in Section 6.

3.1.4. Safety Analysis Set

The Safety Analysis Set includes all subjects who received at least 1 dose of study drug. This is the primary analysis set for safety analyses.

3.1.5. Pharmacokinetic Analysis Set

The Pharmacokinetic (PK) analysis set includes all subjects in the Safety Analysis Set who have at least 1 nonmissing plasma concentration data for filgotinib and/or its metabolite GS-829845. This is the primary analysis set for general PK analyses.

3.1.6. Pharmacokinetic Substudy Analysis Set

The PK Substudy Analysis Set includes all subjects in the Safety Analysis Set who enrolled into the PK Substudy, and have intensive concentration data to provide interpretable results for the specific parameters of interest for the analyte under evaluation. This is the primary analysis set for intensive PK analyses.

3.2. Subject Grouping

For analyses based on the All Randomized Analysis Set and FAS, subjects will be grouped according to the treatment to which they were randomized. For analyses based on the Safety Analysis Set and PP Analysis Set, subjects will be grouped according to actual treatment received. The actual treatment received will differ from the randomized treatment only when their actual treatment differs from randomized treatment for the entire treatment duration of each treatment period.

The treatment groups during the placebo controlled period are:

- Filgotinib 200 mg q.d.
- Filgotinib 100 mg q.d.
- Adalimumab
- Placebo

The treatment groups during the re-randomized period are:

- Filgotinib 200 mg q.d.
- Filgotinib 100 mg q.d.
- Adalimumab
- Placebo switch to filgotinib 200 mg q.d.
- Placebo switch to filgotinib 100 mg q.d.

For the PK Analysis Set, subjects will be grouped according to the actual treatment they received.

3.3. Strata and Covariates

Subjects will be randomly assigned to treatment groups via the interactive web response system (IWRS) in a 3:3:2:3 ratio to filgotinib 200 mg, filgotinib 100 mg, adalimumab or PTM using a stratified randomization schedule. Stratification will be based on the following variables:

- Geographic region (**Group A** includes the following countries: Australia, Belgium, Canada, France, Germany, Ireland, Israel, Italy, Netherlands, New Zealand, Republic of Korea, South Africa, Singapore, Spain, Sweden, Switzerland, United Kingdom, and USA; **Group B** includes the following countries: Bulgaria, Croatia, Czech Republic, Estonia, Georgia, India, Moldova, Romania, Russia, Slovakia, Ukraine, Serbia, Hungary, Latvia and Poland; **Group C** includes the following countries: Argentina, Brazil, Chile, Colombia, Peru, Puerto Rico and Mexico; **Group D** includes the following countries: China, Hong Kong, Malaysia, Philippines, Taiwan, Thailand and Vietnam; **Group E** includes Japan;
- Prior exposure to bDMARDs (Yes or No)
- Presence of RF or anti-CCP Ab (Yes or No) (Presence of RF = No if RF < 15 IU/mL; Presence of anti-CCP Ab = No if anti-CCP Quant < 17 U/mL)

If there are discrepancies in stratification factor values between the IWRS and the clinical database, the values recorded in the clinical database will be used for analyses.

For efficacy endpoints, stratification factors and the baseline value of the efficacy variable(s) will be included as covariates in the efficacy analysis model, as specified in Section 6.

3.4. Examination of Subject Subgroups

The primary and key secondary efficacy endpoints will be examined using the following subgroups (but not limited to the ones listed below):

- Age (on the first dosing date of any study drug, < 65 or ≥ 65)
- Sex at birth (male or female)
- Race
- Baseline weight (< 60 kg, 60 kg to < 100 kg or ≥ 100 kg)
- Geographic region (A, B, C, D or E)
- Prior exposure to bDMARDs (Yes or No)
- Presence of RF or anti-CCP Ab (Yes or No)

- Duration of RA diagnosis on the first dosing date of study drug (< 1 year, 1 year to < 5 years, 5 years to < 10 years or 10 years)
- Disease activity on the first dosing date of study drug (DAS28[CRP] ≤ 5.1 or DAS28[CRP] > 5.1)
- Concurrent use of oral corticosteroids on the first dosing date of study drug (Yes or No)
- High-Sensitivity C-reactive Protein (hsCRP) (≥ 4 mg/L or < 4 mg/L)

Lists of bDMARDs and oral corticosteroids are provided in [Appendix 1](#).

3.5. Multiple Comparisons

The primary endpoint for the study is the proportion of subjects who achieve an ACR20 response at Week 12. The primary analyses will consist of a superiority test of filgotinib 200 mg compared to placebo based on the ACR20 response rate at Week 12.

The following hypothesis testing for secondary analyses will commence after the primary analysis reaches statistical significance, and will be tested according to the hierarchical testing principle at the 2-sided 0.05 level. If a null hypothesis is not rejected, formal sequential testing will be stopped and only nominal significance will be reported for the remaining hypotheses:

- 1) Superiority of filgotinib 100 mg compared to placebo based on ACR20 response rate at Week 12
- 2) Superiority of filgotinib 200 mg compared to placebo based on the change from Baseline in HAQ-DI at Week 12
- 3) Superiority of filgotinib 100 mg compared to placebo based on the change from Baseline in HAQ-DI at Week 12
- 4) Superiority of filgotinib 200 mg compared to placebo based on the proportion of subjects with DAS28(CRP) < 2.6 at Week 12
- 5) Superiority of filgotinib 100 mg compared to placebo based on the proportion of subjects with DAS28(CRP) < 2.6 at Week 12
- 6) Superiority of filgotinib 200 mg compared to placebo based on the change from Baseline in mTSS at Week 24
- 7) Superiority of filgotinib 100 mg compared to placebo based on the change from Baseline in mTSS at Week 24
- 8) Non-inferiority of filgotinib 200 mg compared to adalimumab based on the proportion of subjects with DAS28(CRP) ≤ 3.2 at Week 12

- 9) Non-inferiority of filgotinib 100 mg compared to adalimumab based on the proportion of subjects with DAS28(CRP) ≤ 3.2 at Week 12
- 10) Superiority of filgotinib 200 mg compared to placebo based on the change from Baseline in SF-36 PCS at Week 12
- 11) Superiority of filgotinib 100 mg compared to placebo based on the change from Baseline in SF-36 PCS at Week 12
- 12) Superiority of filgotinib 200 mg compared to placebo based on the change from Baseline in FACIT-Fatigue at Week 12
- 13) Superiority of filgotinib 100 mg compared to placebo based on the change from Baseline in FACIT-Fatigue at Week 12
- 14) Superiority of filgotinib 200 mg compared to adalimumab based on the proportion of subjects with DAS28(CRP) ≤ 3.2 at Week 12
- 15) Superiority of filgotinib 100 mg compared to adalimumab based on the proportion of subjects with DAS28(CRP) ≤ 3.2 at Week 12
- 16) Non-inferiority of filgotinib 200 mg compared to adalimumab based on the proportion of subjects with DAS28(CRP) < 2.6 at Week 12
- 17) Non-inferiority of filgotinib 100 mg compared to adalimumab based on the proportion of subjects with DAS28(CRP) < 2.6 at Week 12
- 18) Superiority of filgotinib 200 mg compared to adalimumab based on the proportion of subjects with DAS28(CRP) < 2.6 at Week 12
- 19) Superiority of filgotinib 100 mg compared to adalimumab based on the proportion of subjects with DAS28(CRP) < 2.6 at Week 12

3.6. Missing Data and Outliers

3.6.1. Missing Data

In general, missing data will not be imputed unless methods for handling missing data are specified. Exceptions are presented in this document.

For missing last dosing date of study drug, imputation rules are described in Section 4.2.1. For partial date of initial RA diagnosis, imputation rules are described in Section 5.2. The handling of missing or incomplete dates for AE onset is described in Section 7.1.5.2, and for prior and concomitant medications in Section 7.4. Imputation rules adopted in the efficacy analyses are specified in Section 6.

3.6.2. Outliers

Outliers will be identified during the data management and data analysis process, but no sensitivity analyses will be conducted. All data will be included in the data analyses.

3.7. Data Handling Conventions and Transformations

In general, age (in years) on the date of the first dose of study drug will be used for analyses and presentation in listings. If an enrolled subject was not dosed with any study drug, the randomization date will be used instead of the first dosing date of study drug. For screen failures, the date the last informed consent was signed will be used for age calculation. If only birth year is collected on the CRF, “01 July” will be used for the unknown birth day and month for the purpose of age calculation. If only birth year and month are collected, “01” will be used for the unknown birth day.

Non-PK Data that are continuous in nature but are less than the lower limit of quantitation (LOQ) or above the upper LOQ will be imputed as follows:

- A value that is 1 unit less than the LOQ will be used to calculate descriptive statistics if the datum is reported in the form of “< x” (where x is considered the LOQ). For example, if the values are reported as < 50 and < 5.0, values of 49 and 4.9, respectively, will be used to calculate summary statistics. An exception to this rule is any value reported as < 1 or < 0.1, etc. For values reported as < 1 or < 0.1, a value of 0.9 or 0.09, respectively, will be used for calculate summary statistics.
- A value that is 1 unit above the LOQ will be used to calculate descriptive statistics if the datum is reported in the form of “> x” (where x is considered the LOQ). Values with decimal points will follow the same logic as above.
- The LOQ will be used to calculate descriptive statistics if the datum is reported in the form of “ x” or “ x” (where x is considered the LOQ).

Natural logarithm transformation will be used for plasma/blood concentrations and analysis of PK parameters. Plasma concentration values that are below the limit of quantitation (BLQ) will be presented as “BLQ” in the concentration data listing. Values that are BLQ will be treated as 0 at predose time points, and one-half the value of the LOQ at postbaseline time points.

The following conventions will be used for the presentation of summary and order statistics:

- If at least 1 subject has a concentration value of BLQ for the time point, the minimum value will be displayed as “BLQ.”
- If more than 25% of the subjects have a concentration data value of BLQ for a given time point, the minimum and Q1 values will be displayed as “BLQ.”
- If more than 50% of the subjects have a concentration data value of BLQ for a given time point, the minimum, Q1, and median values will be displayed as “BLQ.”

- If more than 75% of the subjects have a concentration data value of BLQ for a given time point, the minimum, Q1, median, and Q3 values will be displayed as “BLQ.”
- If all subjects have concentration data values of BLQ for a given time point, all order statistics (minimum, Q1, median, Q3, and maximum) will be displayed as “BLQ.”

PK parameters that are BLQ will be imputed as one-half LOQ before log transformation or statistical model fitting.

3.8. Analysis Visit Windows

3.8.1. Definition of Study Day

The first dose date of individual study drug will be calculated separately for each study drug (ie, filgotinib 200mg, filgotinib 100mg, adalimumab and PTMs) in a treatment group. Study Day 1 is defined as the first dose date of any study drug, which is the minimum of the first dose dates of individual study drugs in a treatment group.

The last dose date of individual study drug will be calculated separately for each study drug in a treatment group. The last dose date for an individual study drug will be the end date on study drug administration CRF for the record where the “study drug was permanently withdrawn” flag is “Yes”. The last dose date of any study drug will be defined as the maximum of the last dose dates of individual study drugs in a treatment group.

Study Day will be calculated from the Study Day 1 and derived as follows:

- For postdose study days: Assessment Date – Study Day 1 + 1
- For days prior to the first dose: Assessment Date – Study Day 1

For subjects who were on placebo and then re-randomized, the On-Filgotinib Study Day 1 is defined as the first dose date of filgotinib which is identified by the first dispense date of filgotinib. The On-Filgotinib Study Day will be calculated from the On-Filgotinib Study Day 1 and derived as follows:

- For postdose study days of filgotinib: Assessment Date – On-Filgotinib Study Day 1 + 1
- For days prior to the first dose of filgotinib: Assessment Date – On-Filgotinib Study Day 1

3.8.2. Analysis Visit Windows

Subject visits may not occur on protocol-specified days. Therefore, for the purpose of analysis, observations will be assigned to analysis windows.

In general, the baseline value will be the last nonmissing value on or prior to the first dose date of study drug, except for the mTSS baseline value. The mTSS baseline value will be derived based on the measurements collected on or prior to the first dose date of study drug + 14 days given the potential delay in scheduling an x-ray assessment. If multiple valid, nonmissing measurements exist in the analysis window as aforementioned, in general, the last nonmissing mTSS value on or prior to the first dose date of study drug will be selected as the baseline value; If all these multiple measurements occur at post first dosing, the value closest to the first dose date will be selected as the baseline value.

For subjects who were on placebo and then re-randomized, the baseline after Week 24 will be the last nonmissing value obtained on or prior to the first dose date of filgotinib, except for the mTSS baseline value. The mTSS baseline value will be derived based on the measurements collected on or prior to the first dose date of filgotinib + 14 days given the potential delay in scheduling an x-ray assessment. If multiple valid, nonmissing measurements exist in the analysis window as aforementioned, in general, the last nonmissing mTSS value on or prior to the first dose date of filgotinib will be selected as the baseline value; If all these multiple measurements occur at post first dosing of filgotinib, the value closest to the first dose date of filgotinib will be selected as the baseline value.

For efficacy endpoints, vital signs, ECG, weight, lipids and safety laboratory data, the analysis visit windows will be applied to data collected during the ‘on-treatment’ period. The ‘on-treatment’ period is defined as the last dose date of any study drug + 7 days.

The analysis windows for on-treatment efficacy endpoints including joint count assessment, HAQ-DI (including subject’s pain assessment), subject’s global assessment (SGA), physician’s global assessment (PGA), serum CRP , exploratory patient reported outcome (PRO), and vital signs, weight, and safety laboratory data (lipid data excluded) are provided in [Table 3-1](#) and [Table 3-2](#).

Table 3-1. Analysis Visit Windows for On-Treatment Joint Count Assessment, HAQ-DI, SGA, PGA, CRP, Exploratory PRO, and Vital Signs, Weight, and Safety Laboratory Data (Lipid Data Excluded) for Subjects who were Initially Randomized to Filgotinib or Adalimumab, and Subjects who were Initially Randomized to Placebo and not Re-randomized

Analysis Visit	Nominal Study Day	Lower Limit	Upper Limit
Baseline	1	(none)	1
Week 2	15	2	22
Week 4	29	23	43
Week 8	57	44	71
Week 12	85	72	92
Week 14	99	93	106
Week 16	113	107	127
Week 20	141	128	155
Week 24	169	156	176
Week 26	183	177	197
Week 30	211	198	232
Week 36	253	233	281
Week 44	309	282	337
Week 52	365	338	365

Table 3-2. Analysis Visit Windows for On-Treatment Joint Count Assessment, HAQ-DI, SGA, PGA, CRP, Exploratory PRO, and Vital Signs, Weight, and Safety Laboratory Data (Lipid Data Excluded) for Subjects who were Initially Randomized to Placebo and Re-randomized

Analysis Visit	Nominal Study Day	Lower Limit	Upper Limit
Baseline	1	(none)	1
Week 2	15	2	22
Week 4	29	23	43
Week 8	57	44	71
Week 12	85	72	92
Week 14	99	93	106
Week 16	113	107	127
Week 20	141	128	155
Week 24	169	156	First Dose Date of Filgotinib - Study Day 1 + 1
Analysis Visit	On-Filgotinib Study Day	On-Filgotinib Lower Limit	On-Filgotinib Upper Limit
Week 26*	15	2	29
Week 30*	43	30	64
Week 36*	85	65	113
Week 44*	141	114	169
Week 52*	197	170	197

* For subjects who were on placebo and re-randomized their analysis window after Week 24 will be assigned according to On-Filgotinib Study Day, On-Filgotinib Lower Limit and On-Filgotinib Upper Limit.

The analysis windows for on-treatment mTSS and lipid data are provided in [Table 3-3](#), [Table 3-4](#), [Table 3-5](#), and [Table 3-6](#).

Table 3-3. Analysis Visit Windows for On-Treatment Lipid Data for Subjects who were Initially Randomized to Filgotinib or Adalimumab, and Subjects who were Initially Randomized to Placebo and not Re-randomized

Analysis Visit	Nominal Study Day	Lower Limit	Upper Limit
Baseline	1	(none)	1
Week 12	85	2	127
Week 24	169	128	267
Week 52	365	268	365

Table 3-4. Analysis Visit Windows for On-Treatment mTSS for Subjects who were Initially Randomized to Filgotinib or Adalimumab, and Subjects who were Initially Randomized to Placebo and not Re-randomized

Analysis Visit	Nominal Study Day	Lower Limit	Upper Limit
Baseline	1	(none)	15
Week 12	85	16	127
Week 24	169	128	267
Week 52	365	268	365

Table 3-5. Analysis Visit Windows for On-Treatment Lipid Data for Subjects who were Initially Randomized to Placebo and Re-randomized

Analysis Visit	Nominal Study Day	Lower Limit	Upper Limit
Baseline	1	(none)	1
Week 12	85	2	127
Week 24	169	128	First Dose Date of Filgotinib - Study Day 1 + 1
Analysis Visit	On-Filgotinib Study Day	On-Filgotinib Lower Limit	On-Filgotinib Upper Limit
Week 52*	197	2	197

* For subjects who were on placebo and re-randomized their analysis window after Week 24 will be assigned according to On-Filgotinib Study Day, On-Filgotinib Lower Limit and On-Filgotinib Upper Limit.

Table 3-6. Analysis Visit Windows for On-Treatment mTSS data for Subjects who were Initially Randomized to Placebo and Re-randomized

Analysis Visit	Nominal Study Day	Lower Limit	Upper Limit
Baseline	1	(none)	15
Week 12	85	16	127
Week 24	169	128	(First Dose Date of Filgotinib + 14) - Study Day 1 + 1
Analysis Visit	On-Filgotinib Study Day	On-Filgotinib Lower Limit	On-Filgotinib Upper Limit
Week 52*	197	16	197

* For subjects who were on placebo and re-randomized their analysis window after Week 24 will be assigned according to On-Filgotinib Study Day, On-Filgotinib Lower Limit and On-Filgotinib Upper Limit.

The analysis windows for On-Treatment Healthcare Resource Utilization Questionnaire (HRUQ), Treatment Satisfaction Questionnaire for Medication (TSQM) and ECG data are provided in [Table 3-7](#) and [Table 3-8](#).

Table 3-7. Analysis Visit Windows for On-Treatment HRUQ,TSQM and ECG Data for Subjects who were Initially Randomized to Filgotinib or Adalimumab, and Subjects who were Initially Randomized to Placebo and not Re-randomized

Analysis Visit	Nominal Study Day	Lower Limit	Upper Limit
Baseline	1	(none)	1
Week 12	85	2	127
Week 24	169	128	211
Week 36	253	212	309
Week 52	365	310	365

Table 3-8. Analysis Visit Windows for On-Treatment HRUQ,TSQM and ECG Data for Subjects who were Initially Randomized to Placebo and Re-randomized

Analysis Visit	Nominal Study Day	Lower Limit	Upper Limit
Baseline	1	(none)	1
Week 12	85	2	127
Week 24	169	128	First Dose Date of Filgotinib - Study Day 1 + 1
Analysis Visit	On-Filgotinib Study Day	On-Filgotinib Lower Limit	On-Filgotinib Upper Limit
Week 36*	85	2	141
Week 52*	197	142	197

* For subjects who were on placebo and re-randomized their analysis window after Week 24 will be assigned according to On-Filgotinib Study Day, On-Filgotinib Lower Limit and On-Filgotinib Upper Limit.

The analysis windows for on-treatment SF-36, FACIT-Fatigue, EQ-5D and WPAI-RA are provided in [Table 3-9](#) and [Table 3-10](#).

Table 3-9. Analysis Visit Windows for On-Treatment SF-36, FACIT-Fatigue, EQ-5D, and WPAI-RA for Subjects who were Initially Randomized to Filgotinib or Adalimumab, and Subjects who were Initially Randomized to Placebo and not Re-randomized

Analysis Visit	Nominal Study Day	Lower Limit	Upper Limit
Baseline	1	(none)	1
Week 4	29	2	57
Week 12	85	58	127
Week 24	169	128	211
Week 36	253	212	309
Week 52	365	310	365

Table 3-10. Analysis Visit Windows for On-Treatment SF-36, FACIT-Fatigue, EQ-5D, and WPAI-RA for Subjects who were Initially Randomized to Placebo and Re-randomized

Analysis Visit	Nominal Study Day	Lower Limit	Upper Limit
Baseline	1	(none)	1
Week 4	29	2	57
Week 12	85	58	127
Week 24	169	128	First Dose Date of Filgotinib - Study Day 1 + 1
Analysis Visit	On-Filgotinib Study Day	On-Filgotinib Lower Limit	On-Filgotinib Upper Limit
Week 36*	85	2	141
Week 52*	197	142	197

* For subjects who were on placebo and re-randomized their analysis window after Week 24 will be assigned according to On-Filgotinib Study Day, On-Filgotinib Lower Limit and On-Filgotinib Upper Limit.

Vital signs, weight, ECG, lipids and safety laboratory data collected in the post-treatment follow-up period will also be summarized. The analysis window for the post-treatment follow-up period is defined as from (the last dose date of any study drug + 8 days) to (the last dose date of any study drug + 30 days). If multiple valid, nonmissing measurements exist in the post-treatment follow-up visit window, then the latest record will be selected for analysis. If the chronological order cannot be determined (eg, more than 1 record on the same day with time missing), for any given subject, the value with the worst severity will be selected for categorical variable, and the average will be taken for continuous variable. Data obtained after last dose date plus 30 days will be excluded from the summaries, but will be included in the listings.

For efficacy endpoints, the same analysis visit windows will be applied to all available data collected during standard of care.

3.8.3. Selection of Non-Efficacy Data in the Event of Multiple Records in an Analysis Visit Window

Depending on the statistical analysis method, single values may be required for each analysis window. For example, change from baseline by visit usually requires a single value, whereas a time-to-event analysis would not require 1 value per analysis window.

If multiple valid, nonmissing, continuous measurements exist in an analysis window, records will be chosen based on the following rules if a single value is needed:

- In general, the baseline value will be the last nonmissing value on or prior to the first dose date of study drug, unless otherwise specified. If multiple measurements occur on the same day, the last nonmissing value prior to the time of first dose of study drug will be considered as the baseline value. If these multiple measurements occur at the same time or the time is not available, the average of these measurements (for continuous data) will be considered the baseline value.
- For postbaseline visits:
 - The record closest to the nominal day for that visit will be selected.
 - If there are 2 records that are equidistant from the nominal day, the later record will be selected.
 - If there is more than 1 record on the selected day, the average will be taken, unless otherwise specified.

If multiple valid, nonmissing, categorical measurements exist in an analysis window, records will be chosen based on the following rules if a single value is needed:

- For baseline, the last available record on or prior to the date of the first dose of study drug will be selected. If there are multiple records with the same time or no time recorded on the same day, the value with the lowest severity will be selected (eg, normal will be selected over abnormal for safety ECG findings).
- For postbaseline visits:
 - The record closest to the nominal day for that visit will be selected.
 - If there are 2 records that are equidistant from the nominal day, the later record will be selected.
 - If there is more than 1 record on the selected day, the value with the worst severity will be selected (eg, abnormal will be selected over normal for safety ECG findings), unless otherwise specified.

The rules for selecting efficacy data in the event of multiple records in an analysis visit window are specified in Section [6.1](#).

4. SUBJECT DISPOSITION

4.1. Subject Enrollment and Disposition

A summary of subject enrollment will be provided by treatment group for each country within each geographic region and investigator within a country. The summary will present the number and percentage of subjects enrolled. For each column, the denominator for the percentage calculation will be the total number of subjects analyzed for that column.

A similar enrollment table will be provided by stratification factor stratum. The denominator for the percentage of subjects in the stratum will be the total number of enrolled subjects. If there are discrepancies in the value used for stratification assignment between the IWRS and the clinical database, the value collected in the clinical database will be used for the summary. A listing of subjects with discrepancies in the value used for stratification assignment between the IWRS and the clinical database at the time of data finalization will be provided.

The randomization schedule used for the study will be provided in a listing and as an appendix to the CSR.

A summary of subject disposition will be provided by treatment group. This summary will present the number of subjects screened, the number of subjects not randomized, the number of subjects who met all eligibility criteria but were not randomized with reasons subjects were not randomized, the number of subjects randomized, and the number of subjects in each of the categories listed below:

- Safety Analysis Set
- Full Analysis Set
- Per-Protocol Analysis Set
- PK Analysis Set
- PK Substudy Analysis Set
- Continuing study drug (Week 24 Analysis only)
- Completed study drug
- Continuing study (Week 24 Analysis only)
- Did not complete study drug with reasons for premature discontinuation of study drug
- Completed study
- Did not complete study with reasons for premature discontinuation from the study

- Completed Week 24 study drug
- Prematurely discontinued study drug prior to Week 24
- Re-randomized

For the status of study drug and study completion and reasons for premature discontinuation, the number and percentage of subjects in each category will be provided. The denominator for the percentage calculation will be the total number of subjects in the Safety Analysis Set corresponding to that column.

For subjects who were on placebo, they will be considered as completed Week 24 study drug if they were re-randomized. For subjects who were on placebo but were not re-randomized, and subjects who remained on the same treatment, they will be considered as completed Week 24 study drug if (last dose date – Study Day 1 + 1) ≤ 156. Otherwise subjects will be considered as not completed Week 24 study drug.

The following by-subject listings will be provided by subject ID number in ascending order to support the above summary tables:

- Reasons for premature study drug or study discontinuation
- Reasons for screen failure (will be provided by screening ID number in ascending order)
- Lot number and kit ID of assigned study drugs

4.2. Extent of Study Drug Exposure and Adherence

Extent of exposure to study drug will be examined by assessing the total duration of exposure to study drug and the level of adherence to the study drug specified in the protocol.

4.2.1. Duration of Exposure to Study Drug

Total duration of exposure to any study drug will be defined as (last dose date of any study drug - first dose date of any study drug + 1), regardless of any temporary interruptions in study drug administration and will be expressed in weeks using up to 1 decimal place (eg, 4.5 weeks).

For subjects with a partial last dosing date (ie, month and year of last dose are known), the latest of the dispensing dates of study drug bottles, study drug start dates and end dates, and the imputed last dose date [day imputed as 15] will be used as the final imputed last dose date. If the subject died and the death date is complete (ie, not partial date) and before the imputed last dose date, the complete death date will be used as the imputed last dose date.

If only year is recorded (ie, month and day of last dose are missing), the latest of the dispensing month of study drug bottles, study drug start month, and study drug end month will be used to impute the unknown last dose month. If the subject died and the death date has month and year available and before the imputed last dose month, then the month of death will be used instead. With the month imputed, the aforementioned method will be used to impute the last dose date.

If subjects are continuing on study drug at Week 24 analysis, the earliest of the date of death or data cutoff date for analysis will be used to impute the last dosing date for the calculation of duration of exposure to study drug.

The total duration of exposure to any study drug will be summarized using descriptive statistics and using the number (ie, cumulative counts) and percentage of subjects exposed through the following time periods: Baseline (Day 1), Week 2 (Day 15), Week 4 (Day 29), Week 8 (Day 57), Week 12 (Day 85), Week 14 (Day 99), Week 16 (Day 113), Week 20 (Day 141), Week 24 (Day 169), Week 26 (Day 183), Week 30 (Day 211), Week 36 (Day 253), Week 44 (Day 309) and Week 52 (Day 365). A 7-day window is applied to the last planned on-treatment visit to match the protocol-specified visit window

Summaries will be provided by treatment group for the Safety Analysis Set. No formal statistical testing is planned.

4.2.2. Adherence to Study Drug

Adherence will be calculated separately for filgotinib 200 mg/PTM (tablets), filgotinib 100 mg/PTM (tablets) and adalimumab/PTM (syringes).

The total number of tablets or syringes administered will be summarized using descriptive statistics.

The presumed total number of tablets or syringes administered to a subject will be determined by the data collected on the drug accountability CRF using the following formula:

Total Number of Tablets Administered =

(No. of Tablets Dispensed) - (No. of Tablets Returned)

Total Number of Syringes Administered =

(No. of Syringes Dispensed) - (No. of Syringes Returned)

If a bottle or a packaging kit is dispensed and the bottle or packaging kit is returned empty, then the number of tablets/syringes returned will be entered as zero. If a bottle or a packaging kit is dispensed but not returned (missing), then the number of tablets/syringes returned will be counted as zero.

4.2.2.1. On-Treatment Adherence

The level of on-treatment adherence to the study drug will be determined by the total amount of study drug administered relative to the total amount of study drug expected to be administered during a subject's actual on-treatment period based on the study drug regimen.

The level of on-treatment adherence will be expressed as a percentage using the following formula:

$$\text{On-Treatment Adherence (\%)} = \left(\frac{\text{Total Amount of Study Drug Administered}}{\text{Study Drug Expected to be Administered on Treatment}} \right) \times 100$$

Note: If calculated adherence is greater than 100%, the result will be set to 100%.

Study drug expected to be administered for filgotinib 200 mg/PTM (tablets) = 1 × total duration of exposure to any study drug (days).

Study drug expected to be administered for filgotinib 100 mg/PTM (tablets) = 1 × total duration of exposure to any study drug (days).

Study drug expected to be administered for adalimumab/PTM (syringes) = ceil[total duration of exposure to any study drug (days) / 14].

For subjects in placebo group who were re-randomized, the switched study drug expected to be administered is defined as:

Study drug expected to be administered for PTM (tablets) = 1 × ((first dose date of filgotinib – 1 – first dose date of any study drug) + 1).

Study drug expected to be administered for filgotinib 100 mg/ filgotinib 200 mg = 1 × ((last dose date of any study drug – first dose date of filgotinib) + 1).

On-treatment adherence will be calculated up to Week 12, up to Week 24 and up to Week 52, respectively.

Descriptive statistics for the level of on-treatment adherence with the number and percentage of subjects belonging to adherence categories (eg, < 80%, 80 to < 90%, 90%) will be provided by treatment group for the Safety Analysis Set.

Categorical displays will be presented for the number of subjects who are at least 80% adherent to their study drug regimen (ie, adherence is ≥ 80% for each study drug).

No formal statistical testing is planned.

A by-subject listing of study drug administration and drug accountability will be provided separately by subject ID number (in ascending order) and visit (in chronological order).

4.3. Protocol Deviations

Subjects who did not meet the eligibility criteria for study entry, but enrolled in the study will be summarized regardless of whether they were exempted by the sponsor or not. The summary will present the number and percentage of subjects who did not meet at least 1 eligibility criterion and the number of subjects who did not meet specific criteria by treatment group based on the All Randomized Analysis Set. A by-subject listing will be provided for those subjects who did not meet at least 1 eligibility (inclusion or exclusion) criterion. The listing will present the eligibility criterion (or criteria if more than 1 deviation) that subjects did not meet and related comments, if collected.

Protocol deviations occurring after subjects entered the study are documented during routine monitoring. The number and percentage of subjects with important protocol deviations by deviation reason (eg, nonadherence to study drug, violation of select inclusion/exclusion criteria) will be summarized by treatment group for the All Randomized Analysis Set. A by-subject listing will be provided for those subjects with important protocol deviation.

5. BASELINE CHARACTERISTICS

5.1. Demographics and Other Baseline Characteristics

Subject demographic and other baseline characteristics variables will be summarized by treatment group and overall using descriptive statistics for continuous variables, and using number and percentage of subjects for categorical variables. The summary of demographic and other baseline characteristics data will be provided for the Safety Analysis Set for the following:

- Age (on the first dose date of any study drug)
- Age group (< 65 years, ≥ 65 years)
- Sex at birth (male, female)
- Race
- Ethnicity (Hispanic or Latino, not Hispanic or Latino)
- Geographic region and country
- Weight (kg)
- Height (cm)
- Body mass index (BMI; in kg/m²)
- Smoking status

A by-subject demographic and other baseline characteristics listing, including the informed consent date, will be provided by subject ID number in ascending order.

5.2. Baseline Disease Characteristics

Baseline disease characteristics include:

- Duration of RA from diagnosis (years)

Calculated as ((first dose date) – (date of initial diagnosis) + 1 day) / 365.25. If the date of initial diagnosis is incomplete, then the following rules will be applied:

— missing day: use the first of the month

— missing month: use January

- Presence of RF (Yes/No)

- Presence of anti-CCP Ab (Yes/No)
- Presence of both RF and anti-CCP Ab (Yes/No)
- Prior exposure to bDMARDs (Yes/No)
- Concurrent oral corticosteroids use on the first dosing date (Yes/No): n (%)
 - Oral corticosteroids dose, mg/day, expressed as prednisone-equivalent dose
- Concurrent MTX use on the first dosing date (Yes/No): n (%)
 - Dose of MTX, mg/week
- Concurrent anti-malarials use on the first dosing date (Yes/No)
- Swollen joint count based on 66 joints (SJC66)
- Tender joint count based on 68 joints (TJC68)
- Swollen joint count based on 28 joints (SJC28)
- Tender joint count based on 28 joints (TJC28)
- HAQ-DI total score
- DAS28(CRP)
- SF-36 physical component summary (PCS) score
- SF-36 mental component summary (MCS) score
- FACIT-Fatigue
- Subject's pain assessment (by visual analog scale [VAS] in mm)
- Subject's global assessment of disease activity [SGA] (by VAS in mm)
- Physician's global assessment [PGA] (by VAS in mm)
- Simplified Disease Activity Index (SDAI)
- Clinical Disease Activity Index (CDAI)
- hsCRP (mg/L)

- hsCRP 6 mg/L (Yes/No)
- mTSS
 - Erosion score
 - Joint space narrowing (JSN) score
- Subject with erosion defined as erosion score > 0 (Yes/No)

A list of anti-malarials is provided in [Appendix 1](#). The baseline disease characteristics will be summarized by treatment group and overall using descriptive statistics for continuous variables and using number and percentage of subjects for categorical variables. The summary of baseline disease characteristics will be provided for the Safety Analysis Set.

A by-subject listing of baseline disease characteristics will be provided by subject ID number in ascending order.

5.3. Medical History

Medical history collected at screening will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) 21.0.

Medical history will be summarized by system organ class (SOC), preferred term (PT), treatment group, and overall. Subjects who report 2 or more medical history items that are coded to the same SOC and/or PT will be counted only once by the unique coded term in the summary.

In addition, numbers and percentages of subjects who have any first degree relatives that had experienced myocardial infarction or stroke before the age of 50 years, experienced myocardial infarction or stroke before the age of 50 years, or have diabetes (type I or II) will be summarized.

The summary will be provided for the Safety Analysis Set. No formal statistical testing is planned.

A by-subject listing of medical history will be provided by subject ID number.

6. EFFICACY ANALYSES

6.1. General Considerations

The primary analysis set for efficacy analyses will be the FAS, defined in Section 3.1.2.

Efficacy analysis will generally be conducted on the following 2 datasets:

- 1) On-treatment data as specified in Section 3.8.2 with exclusion of the observations described as the following. This is the primary analysis dataset for efficacy analysis.
 - For subjects who continued study drug BUT did not achieve at least 20% improvement from Baseline in both SJC66 and TJC68 at
 - Nominal Week 14 visit, then efficacy data collected after nominal Week 14 visit will be excluded from the primary analysis, OR
 - Nominal Week 12 visit if subjects missed Week 14 visit or the response status cannot be determined due to missing SJC66 or TJC68 value at Week 14, then efficacy data collected after nominal Week 16 visit will be excluded from the primary analysis, OR
 - Nominal Week 16 visit if subjects missed both Week 12 and Week 14 visits or the response status cannot be determined due to missing SJC66 or TJC68 value at both Week 12 and Week 14 visits, then efficacy data collected after nominal Week 16 visit will be excluded from the primary analysis

If subjects missed all three visits (Week 12, Week 14 and Week 16) or the response status cannot be determined at all of these three visits, all the efficacy data collected will be included for analysis

 - Subjects who continued on study drug will be evaluated for loss of therapeutic response from nominal Week 30 visit through nominal Week 52 visit. For subjects who failed to maintain at least a 20% improvement from Baseline in SJC66 and TJC68 (which is confirmed at 2 consecutive visits, and a missed visit will not count against them), efficacy data collected after the second consecutive visit will be excluded from the primary analyses.
- 2) All available data (including data collected under standard of care).

Estimands:

Two efficacy estimands, composite estimand and treatment policy estimand are defined for the primary and key secondary efficacy endpoints, respectively.

The **Composite Estimand** is defined as following. This is the primary estimand for efficacy endpoints.

- 1) Population: Subjects in the FAS.
- 2) Variable: Primary and key secondary endpoints as well as some other secondary endpoints (see details in Section 6.2, 6.3 and 6.4)
- 3) Intercurrent events: The following intercurrent events are taken into account:
 - If a subject takes standard of care medications due to inadequate response or discontinues from study treatment, treat data as missing from the point of inadequate response or study drug discontinuation (ie, on-treatment data defined above).
 - If a subject discontinues from the study, treat data as missing from the point of loss to follow-up onward.
- 4) Population-level summary: proportion difference for binary efficacy endpoints or mean difference in change from baseline for continuous efficacy endpoints between each filgotinib group and placebo group or adalimumab group if applicable.

The **Treatment-Policy Estimand** is defined as following. This is the secondary estimand for efficacy endpoints.

- 1) Population: Subjects in the FAS.
- 2) Variable: Primary and key secondary endpoints as well as some other secondary endpoints (see details in Section 6.2, 6.3 and 6.4)
- 3) Intercurrent events: The occurrence of an intercurrent event is irrelevant. All observed values will be used regardless of occurrence of an intercurrent event.
 - All observed values will be used regardless of occurrence of an intercurrent event (ie, All available data defined above).
 - If a subject discontinues from the study, treat data as missing from the point of loss to follow-up onward.
- 4) Population-level summary: Proportion difference for binary efficacy endpoint or mean difference in change from baseline for continuous efficacy endpoints between each filgotinib group and placebo group or adalimumab group if applicable.

The other secondary endpoints specified in both estimands include ACR50, ACR70, and the individual components of the ACR response.

To handle the missing data caused by the intercurrent events, the following analyses will be performed for both estimands:

- For binary endpoints, missing data will be treated as non-responder for the primary analysis. Sensitivity analyses including observed data only, last observation carry forward (LOCF), multiple imputation, and tipping point methods will be applied.
- For continuous endpoints, missing data will be handled using a mixed-effects model for the primary analysis. Sensitivity analyses, including using multiple imputation and tipping point methods, will be applied.

In addition, analyses will be performed for the primary and key secondary endpoints by replacing the population in both estimands with the Per-Protocol analysis set as defined in Section 3.1.3. For these analyses, the binary missing data will be imputed as non-responder and the continuous missing data will be handled using a mixed-effects model.

Selection of Efficacy Data in the Event of Multiple Records in an Analysis Visit Window

If multiple valid, nonmissing efficacy measurements exist in an analysis window, records will be chosen based on the following rules if a single value is needed:

- The record closest to the nominal day for that visit will be selected
- If there are 2 records that are equidistant from the nominal day, or more than 1 record (with time known) on the selected day, the latest record will be taken
- If chronological order cannot be determined (eg, more than 1 record on the same day with time missing), for any given subject, the worst outcome will be selected.

Calculation of Composite Endpoints

For the calculation of composite endpoints including DAS28(CRP), ACR20/50/70, ACR-N, SDAI, and CDAI, we use the following steps unless otherwise specified:

- Step 1: Assign individual components to analysis visit windows defined in Section 3.8.2
- Step 2: Within each analysis visit window, select the component-level data based on the rules for selecting efficacy data as above
- Step 3: Calculate the composite endpoint based on the selected component-level data in Step 2.

Missing Data Imputation

Below are the descriptions for the imputation methods that will be used throughout the efficacy analyses:

- Observed case (OC): Missing values remain missing. For the categorical composite endpoints, in the case that some components are missing, the composite endpoint assessment will be derived based on the non-missing components. If non-missing components are not sufficient to determine final composite endpoint, then the composite endpoint will be set as missing. For continuous composite endpoints (including ACR-N), if any components are missing, the composite endpoints will be set as missing.
- Last observation carried forward (LOCF): Baseline measurements will not be carried forward to postbaseline. Only postbaseline measurements will be LOCF. For the composite endpoints, the last nonmissing postbaseline observation will be carried forward to subsequent visits for each individual component first, and then calculate the composite endpoints using individual components imputed by LOCF as described above. If a subject does not have a nonmissing observed record for a postbaseline visit, the last postbaseline record prior to the missed visit will be used for this postbaseline visit. If the last nonmissing observation prior to the missing visits cannot be determined due to multiple measurements occurring at the same time or the time not available within the same day, the worst outcome will be used for LOCF. If missing components still exist after LOCF, the composite endpoints will be calculated using the same rules as described in OC.
- Non-responder imputation (NRI): For all binary response measurements, starting from OC, all missings will be set as non-responders.

If a subject only has baseline measurements, LOCF and OC analyses will not include this subject. But this subject will be treated as non-responder in NRI analyses.

6.1.1. Tender/Swollen Joint Counts (TJC/SJC)

Tender joint count based on 68 joints (TJC68) and swollen joint count based on 66 joints (SJC66) will be collected during the course of the study. The assessment for each joint will be from the following selections: Tender Only, Swollen Only, Tender and Swollen, Joint Non-Evaluable or Missing, or Not Tender or Swollen.

Individual joint with missing assessment will not be imputed. If at least half of the joints are assessed at a given visit, the prorated tender and swollen joint counts will be calculated using the following formula:

$$TJC68 = \frac{\text{Total number of tender joints}}{68 - (\text{Number of nonevaluable or missing joints out of 68 joints})} \times 68$$

$$SJC66 = \frac{\text{Total number of swollen joints}}{66 - (\text{Number of nonevaluable or missing joints out of 66 joints})} \times 66$$

If less than half of joints are assessed at a given visit, joint counts are treated as missing for that visit.

A more abbreviated assessment considering 28 joints as listed in [Table 6-1](#) for both tenderness and swelling will also be conducted (as part of the TJC68 and SJC66 assessment), denoted as TJC28 and SJC28, respectively.

Table 6-1. Composition of the 28 Joints

Joints	Number
Shoulder Joints (Left and Right)	2
Elbow Joints (Left and Right)	2
Wrist Joints (Left and Right)	2
Metacarpophalangeal Joints I-V (Left and Right) – hands only	10
Proximal Interphalangeal Joints I-V (Left and Right) – hands only	10
Knee Joints (Left and Right)	2

If there exist non-evaluable or missing joints among the 28 joints, similar prorated tender and swollen joint counts will be calculated as follows:

$$TJC28 = \frac{\text{Total number of tender joints}}{28 - (\text{Number of nonevaluable or missing joints out of 28 joints})} \times 28$$

$$SJC28 = \frac{\text{Total number of swollen joints}}{28 - (\text{Number of nonevaluable or missing joints out of 28 joints})} \times 28$$

If less than half of the 28 joints are assessed at a given visit, TJC28 and SJC28 are treated as missing for that visit.

6.1.2. Global Assessment of Disease Activity

Subject’s Global Assessment of Disease Activity (SGA) and Physician’s Global Assessment of Disease Activity (PGA) based on a 0-100 mm visual analog scale (VAS) will be recorded during the study, with 0 indicating “no disease activity” and 100 indicating “maximum disease activity” (or similar description of disease severity).

6.1.3. Health Assessment Questionnaire Disability Index (HAQ-DI)

The HAQ-DI score is defined as the average of the scores of eight functional categories (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities), administered by the subject. Responses in each functional category are collected as: without any difficulty; with some difficulty; with much difficulty; unable to do a task in that area and with or without aids or devices. The HAQ-DI score ranges from 0 (no disability) to 3 (completely disabled), when 6 or more categories are non-missing. Detailed algorithm for calculating HAQ-DI score is described in [Appendix 2](#).

HAQ-DI also includes a separate pain assessment and subject will be requested to mark the severity of the pain in the past week on a 0-100 mm VAS, with 0 indicating “no pain” and 100 indicating “severe pain”.

6.2. Primary Efficacy Endpoint

The primary efficacy endpoint is the proportion of subjects who achieve ACR20 response at Week 12.

6.2.1. Definition of the Primary Efficacy Endpoint

A subject achieves ACR20 response when this subject has

- 20% improvement from baseline in TJC68, AND
- 20% improvement from baseline in SJC66, AND
- 20% improvement from baseline in at least 3 of the following 5 items:
 - 1) PGA
 - 2) SGA
 - 3) Subject’s pain assessment
 - 4) HAQ-DI score
 - 5) hsCRP

Percent improvement from baseline at a postbaseline visit is calculated as follows for all 7 components mentioned above:

$$\% \text{ improvement} = \frac{\text{baseline value} - \text{postbaseline value}}{\text{baseline value}} \times 100$$

If the baseline value is 0 then the percent improvement from baseline is set to missing.

In the case that some ACR20 components are missing, the ACR20 assessment will be based on the non-missing components. If non-missing components are not sufficient to determine ACR20 response, then the ACR20 response will be considered as missing.

6.2.2. Statistical Hypothesis for the Primary Efficacy Endpoint

In the primary analysis, the ACR20 response rate at Week 12 in the filgotinib 200 mg group will be compared to placebo group for a superiority test at the 2-sided 0.05-level. If we denote the ACR20 response rate at Week 12 in the filgotinib 200 mg group and placebo group as P_1 and P_2 , respectively, the null and alternative hypotheses for the superiority test on the primary efficacy endpoint are as follows:

$$H_0: P_1 = P_2$$

vs

$$H_1: P_1 > P_2$$

6.2.3. Primary Analysis of the Primary Efficacy Endpoint

To test for superiority of filgotinib 200 mg group versus placebo control group in proportion of subjects who achieve ACR20 at Week 12, a logistic regression analysis with treatment groups and stratification factors in the model will be used. The model will include all treatment groups. Subjects who do not have sufficient measurements to establish efficacy at Week 12 will be considered as failures (ie, NRI). The p-value from the logistic regression model for testing the superiority of filgotinib 200 mg as compared to placebo will be provided. The 2-sided 95% confidence interval (CI) of the ACR20 response rate at Week 12 based on normal approximation with the sample variance will be provided for each treatment group. In addition, non-stratified ACR20 response rate difference along with its 95% CI calculated based on the normal approximation with the pooled sample variance will be provided. [Appendix 8](#) provides samples SAS model statements for constructing the confidence interval for the proportion.

The comparisons of filgotinib 100 mg groups versus placebo group in the proportion of subjects achieving ACR20 at Week 12 will also be conducted with the similar logistic regression model with NRI as aforementioned.

The number and percentage of ACR20 non-responders observed and non-responders due to missing at Week 12 will also be summarized respectively by treatment.

For subjects with observed ACR20 outcomes (ie, responders and observed non-responders) at Week 12, actual values and change from Baseline at Week 12 in individual components, including TJC68, SJC66, SGA, PGA, Subject's pain assessment, hsCRP, will be summarized using descriptive statistics (sample size, mean, SD, median, Q1, Q3, minimum, and maximum) by treatment.

The proportions of subjects achieving ACR20 (using NRI) will be plotted over time from Baseline through Week 24 by treatment and by visit.

6.2.4. Sensitivity Analysis of the Primary Endpoint

Sensitivity analyses of the primary efficacy endpoint will be performed.

6.2.4.1. Per-protocol Analyses

To evaluate the impact of study conduct on the primary analysis, the proportion of subjects who achieve ACR20 at Week 12 will be analyzed based on the PP Analysis Set as defined in Section 3.1.3 using the logistic regression analysis with NRI for the comparisons of each filgotinib group versus the placebo group. The p-value from the logistic regression model will be provided. The 2-sided 95% CI of the ACR20 response rate at Week 12 based on normal approximation with the sample variance for each treatment group will be provided. In addition, the non-stratified ACR20 response rate difference along with its 95% CI calculated based on the normal approximation with the pooled sample variance will also be provided.

6.2.4.2. Missing Data Imputation Analyses

To evaluate the impact of missing data on the ACR20 response rate at Week 12, the following missing value imputation methods will be used:

- The analysis specified in Section 6.2.3 will be performed by using OC and LOCF methods as described in Section 6.1.
- Multiple imputation (MI): The MI procedure replaces each missing binary ACR20 value with a set of plausible values that represent the uncertainty about the right value to impute. Twenty imputed datasets will be generated based on logistic regression models with starting seed 12345. These multiple imputed data sets are then analyzed by using the same method for the primary analysis for complete data as specified in Section 6.2.3. The results from each set of imputed data sets will then be combined using Rubin's rule {Rubin 1987}. The stratification factors will be included in the imputation model as covariates and data at post-baseline visits up to the time point of interest will be included in the longitudinal model.

- Tipping point analysis: To assess the robustness of analysis results under MNAR (missing not at random) assumption, a delta-adjusting pattern-mixture approach for tipping point analysis {Ratitch 2013} will be conducted for the primary efficacy endpoint. The impact from missing data on the comparisons in proportion of subjects achieving ACR20 at Week 12 between filgotinib groups and placebo control group will be examined, by adjusting for stratification factors. The proposed method will perform a series of analyses with a range of different values of the shift parameter applied to the imputed datasets at which the conclusion about the statistical significance of the estimated treatment effect will be altered. Specifically, a tipping point analysis is characterized by a pair of sequences (one sequence associated with missing data in the placebo group and the other associated with missing data in the filgotinib group). In the first step for both sequences, the missing data in both treatment groups are imputed under the MAR assumption. For each subsequent step of the placebo sequence, the missing data is imputed assuming the missing data is incrementally more favorable than in the previous step of that sequence. Similarly, for each subsequent step of the active sequence, the missing data is imputed assuming the missing data is incrementally less favorable than in the previous step of that sequence. Appendix 6 provides sample SAS model statements for the tipping point analysis with starting seed. Each value is classified as either ‘altering the study’s conclusion’ or tips, ‘keeping the study’s conclusion unchanged’. The tipping points that alter the statistical conclusion will be provided. For each value, 20 imputed data sets will be generated. The same analysis method for the primary analysis as specified in Section 6.2.3 will be applied when analyzing adjusted data generated under the different values.

6.2.5. Subgroup Analysis of the Primary Endpoint

Subgroup analyses comparing each filgotinib dose group to the placebo group will be performed at Week 12 and Week 24 for the primary endpoint, for the subgroups specified in Section 3.4.

The proportion of subjects who achieve ACR20 will be analyzed using the Fisher’s exact test based on the NRI method for treatment group comparison. The number and percentage of subjects with ACR20 will also be provided for each treatment group within the subgroups.

6.3. Key Secondary Efficacy Endpoints

The key secondary efficacy endpoints are:

- Change from Baseline in HAQ-DI score at Week 12
- The proportion of subjects who achieve DAS28(CRP) < 2.6 at Week 12
- Change from Baseline in mTSS at Week 24

- The proportion of subjects who achieve DAS28(CRP) 3.2 at Week 12
- Change from Baseline in SF-36 physical component summary (PCS) score at Week 12
- Change from Baseline in FACIT-Fatigue score at Week 12

6.3.1. Definition of Key Secondary Efficacy Endpoints

6.3.1.1. Disease Activity Score for 28 Joint Count using CRP

The DAS28(CRP) score is calculated as follows:

$$\text{DAS28(CRP)} = 0.56\sqrt{\text{TJC28}} + 0.28\sqrt{\text{SJC28}} + 0.36 \ln(\text{CRP} + 1) + 0.014 \times \text{SGA} + 0.96,$$

where

CRP = hsCRP measurement (mg/L)

SGA = subject's global assessment of disease activity on a 0-100 VAS

Higher DAS28(CRP) value indicates more severe disease activity.

No component-level imputation will be performed for the calculation of DAS28(CRP) for the primary analyses. If any components are missing, the DAS28(CRP) will be set as missing.

6.3.1.2. Modified Total Sharp Score (mTSS)

Subject's radiographs of bilateral hands, wrists and feet will be taken at screening and protocol specified visits. The radiographs will be evaluated through central review by independent joint assessors using the modified total Sharp Score (mTSS) method. The mTSS (range [0, 448]) is defined as the erosion score (range [0, 280]) plus the joint space narrowing (JSN) score (range [0, 168]). Detailed algorithm for calculating mTSS, erosion score and JSN score is described in [Appendix 3](#).

6.3.1.3. 36-Item Short-form Health Survey

The SF-36 Version 2 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire that yields an 8 health domains (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with higher scores indicating better health status or functioning. In addition, 2 summary scores, the physical component summary (PCS) score and the mental component summary (MCS) score will be evaluated based on the 8 SF-36 domains.

6.3.1.4. FACIT-Fatigue

The FACIT-Fatigue scale is a brief, 13-item, symptom-specific questionnaire that specifically assesses the self-reported severity of fatigue and its impact upon daily activities and functioning in the past 7 days. The FACIT-Fatigue uses 0 (“not at all”) to 4 (“very much”) numeric rating scales. Negatively stated items are reversed by subtracting the response from “4” before being added to obtain a total score. Scores range from 0 to 52 with higher scores indicating less fatigue. In the case of missing response for some items in the questionnaire, if at least half of the items (ie, 7 of 13 items) were answered at a given visit, the prorated score will be calculated and used in the analysis.

6.3.2. Analysis Methods for Key Secondary Efficacy Endpoints

Hypothesis testing on the key secondary efficacy endpoints will commence after the testing on the primary efficacy endpoint reaches statistical significance, and will be performed according to the hierarchical testing principle at the 2-sided 0.05 level as described in Section 3.5. If a null hypothesis is not rejected, formal sequential testing will be stopped and only nominal significance will be reported for the remaining hypotheses.

For non-inferiority test of the proportion of subjects who achieve DAS28(CRP) 3.2 at Week 12, the approach proposed by {Liu 2014} will be used to demonstrate that each filgotinib dose preserves more than 50% of the effect of adalimumab on the response rate of DAS28 (CRP) 3.2 at Week 12 using NRI. Let π_T , π_C and π_P denote the true response rates of DAS28 (CRP) 3.2 for filgotinib, adalimumab, and placebo respectively, at Week 12, with corresponding variances σ_T^2 , σ_C^2 and σ_P^2 . The non-inferiority null hypothesis is

$$H_{0,NI} : \frac{\pi_T - \pi_P}{\pi_C - \pi_P} \geq 0.5$$

According to {Liu 2014}, non-inferiority (filgotinib preserves more than 50% of the effect of adalimumab) at 2-sided 0.05 level will be claimed if $Z_{NI} > z_*$, where

$$Z_{NI} = \frac{\hat{\pi}_T - 0.5\hat{\pi}_C - (1-0.5)\hat{\pi}_P}{\sqrt{\hat{\sigma}_T^2 + 0.5^2\hat{\sigma}_C^2 + (1-0.5)^2\hat{\sigma}_P^2}}$$
 and z_* is the 97.5 quantile of the standard normal distribution.

Note that the “hat” (^) denotes the estimated values of each parameter at Week 12.

The non-inferiority test of the proportion of subjects who achieve DAS28(CRP) < 2.6 at Week 12 will be performed.

For the superiority test of the proportion of subjects who achieve DAS28(CRP) < 2.6 at Week 12, the similar logistic regression analysis with the same model specification as the primary endpoint analysis described in Section 6.2.3 will be adopted for the treatment comparisons. The model will include all treatment groups. The NRI method will be used to impute missing value. Comparison will be made between each filgotinib dose group and placebo group. The p-value from the logistic regression model will be reported for statistical inference. The 2-sided 95% CI of response rate based on normal approximation with the sample variance will be provided for each treatment group. In addition, non-stratified response rate difference along with its 95% CI calculated based on the normal approximation with the pooled the sample variance will be provided. The superiority test of the proportion of subjects who achieve DAS28(CRP) \geq 3.2 or DAS28(CRP) < 2.6 at Week 12 will be performed in the similar way, and the comparison will be made between each filgotinib dose group and adalimumab group.

The change from Baseline in HAQ-DI at Week 12 will be analyzed using the mixed-effects model for repeated measures (MMRM) that includes data at postbaseline visits up to the time point of interest. Subjects that have a baseline value and at least 1 postbaseline value are included in the analysis. The MMRM models will be used to evaluate treatment effect on change score from Baseline, with baseline value, stratification factors, treatment, visit, and treatment by visit interaction included as fixed effects and subject being the random effect. The MMRM model will include all treatment groups. An unstructured variance-covariance matrix will be used. The Kenward-Roger method will be used to estimate the degrees of freedom. Missing change scores due to missing study visits, early withdrawal or treatment reassignment will not be otherwise imputed using the MMRM approach. The least squares (LS) means and 95% CIs of the difference in mean change from Baseline in HAQ-DI between each filgotinib dose group and placebo group from MMRM will be provided.

The change from Baseline in mTSS, erosion score and JSN score at Week 24, and change from Baseline in SF-36 PCS score and FACIT-Fatigue score at Week 12 will be analyzed using similar MMRM method as HAQ-DI, by including data at postbaseline visits up to the time point of interest. To test for a treatment difference between each filgotinib dose group and placebo, LS mean difference along with 95% CI and p-values from the MMRM model will be presented.

The proportions of subjects achieving DAS28(CRP) \geq 3.2 (using NRI), and proportions of subjects achieving DAS28(CRP) < 2.6 (using NRI) will be plotted over time by treatment. Plots of mean \pm SD of changes from Baseline in HAQ-DI, mTSS, erosion score, JSN score, SF-36 PCS and FACIT-Fatigue over time will be presented respectively. Cumulative percentile plots will be provided for change from baseline in mTSS.

6.3.3. Sensitivity Analysis for Key Secondary Efficacy Endpoints

6.3.3.1. Per-Protocol Analysis

The analyses of the key secondary efficacy endpoints (except for the change from baseline in mTSS at Week 24) will be repeated using the PP Analysis Set specified in Section 3.1.3.

6.3.3.2. Missing Data Imputation Analyses

The following imputation methods will be explored:

- Change from Baseline in HAQ-DI score at Week 12
 - 1) MI: All subjects with baseline measurement will be included. The MI procedure replaces each missing value with a set of plausible values that represent the uncertainty about the right value to impute. Twenty imputed datasets will be generated based on linear regression models on observed HAQ-DI scores with starting seeds 123 and 465. These 20 imputed data sets are then analyzed by using the analysis method specified in Section 6.3.2 for complete data. The results from each imputed data set will then be combined using Rubin's rule {Rubin 1987}. Stratification factors and baseline values will be included in the imputation model as covariates, and data at baseline and all post-baseline visits up to the time point of interest visit will be included in the longitudinal model.
 - 2) Tipping point analysis: All subjects with baseline measurement will be included. To assess the robustness of analysis results for change from Baseline in HAQ-DI at Week 12 under MNAR assumption, a set of the shift parameters that adjust the imputed values will be examined {Yuan 2014}. The shift parameter that alters the study conclusion for the hypothesis testing for change from Baseline in HAQ-DI at Week 12 under the MAR assumption will be reported as the tipping point and provided. The tipping point analysis will be conducted by iteratively assigning plausible outcomes to missing values for subjects in different treatment group independently until the conclusion is reversed (eg, analyses are no longer statistically significant). Appendix 7 provides sample SAS model statements for the tipping point analysis with starting seeds. The same analysis method for the primary analysis as specified in Section 6.3.2 will be applied when analyzing adjusted data generated under each plausible shift parameter.
- Proportion of subjects who achieve DAS28(CRP) < 2.6 at Week 12
 - 1) The analysis using the same logistic regression model specified in Section 6.3.2 will be performed by using OC and LOCF methods as described in Section 6.1.
 - 2) MI: All subjects with baseline measurement will be included. The MI procedure replaces each missing composite DAS28(CRP) value with a set of plausible values that represent the uncertainty about the right value to impute. Baseline value and stratification factors will be included in the imputation model as covariates, and data at baseline and post-baseline visits up to the time point of interest will be included in the longitudinal model. The multiple imputed datasets will be generated. These multiple imputed data sets are then used to identify subjects with DAS28(CRP) < 2.6 at Week 12, and analyzed by using the analysis method specified in Section 6.3.2 for complete data. The results from each set of imputed data sets will then be combined using Rubin's rule {Rubin 1987}.
 - 3) Tipping point analysis: Similar modified tipping point method as described in Section 6.2.4.2 will be applied to DAS28(CRP) < 2.6 response rate at Week 12.

- Change from Baseline in mTSS at Week 24
 - 1) MI: Similar MI procedure used for analyzing the change from Baseline in HAQ-DI score at Week 12 will be performed.
 - 2) Tipping point analysis: Similar tipping point analysis method used for analyzing the change from Baseline in HAQ-DI score at Week 12 will be performed.
- Non-inferiority analysis of the proportion of subjects who achieve DAS28(CRP) ≥ 3.2 or DAS28(CRP) < 2.6 at Week 12
 - 1) The non-inferiority analysis using the same test specified in Section 6.3.2 will be performed by using OC and LOCF methods as described in Section 6.1.
 - 2) MI: Similar MI procedure used for superiority test of the proportion of subjects who achieve DAS28(CRP) < 2.6 at Week 12 will be performed. The multiple imputed data sets will be analyzed by using the non-inferiority analysis specified in Section 6.3.2 for complete data. The results from each set of imputed data sets will then be combined.
 - 3) Tipping point analysis: Similar modified tipping point method as described in Section 6.2.4.2 will be applied to DAS28(CRP) ≥ 3.2 or DAS28(CRP) < 2.6 response rate at Week 12. The non-inferiority analysis specified in Section 6.3.2 will be applied when analyzing adjusted data generated under the different δ values.
- Change from Baseline in SF-36 PCS at Week 12
 - 1) MI: Similar MI procedure used for analyzing the change from Baseline in HAQ-DI score at Week 12 will be performed.
 - 2) Tipping point analysis: Similar tipping point analysis method as for analyzing the change from Baseline in HAQ-DI score at Week 12 will be performed.
- Change from Baseline in FACIT-Fatigue at Week 12
 - 1) MI: Similar MI procedure used for analyzing the change from Baseline in HAQ-DI score at Week 12 will be performed.
 - 2) Tipping point analysis: Similar tipping point analysis method as for analyzing the change from Baseline in HAQ-DI score at Week 12 will be performed.

6.3.3.3. Sensitivity Analyses of Non-inferiority Test

For non-inferiority test of the proportion of subjects who achieve DAS28(CRP) ≥ 3.2 or DAS28(CRP) < 2.6 at Week 12, different margins that are higher than 0.5, and up to 0.99 will be used in the non-inferiority analysis. The null hypothesis is

$$H_{0,NI} : \frac{\pi_T - \pi_P}{\pi_C - \pi_P}$$

According to {Liu 2014}, non-inferiority with margin δ at 2-sided 0.05 level will be claimed if $Z_{NI} > z_*$, where

$$Z_{NI} = \frac{\hat{\pi}_T - \hat{\pi}_C - (1 - \delta)\hat{\pi}_P}{\sqrt{\hat{\sigma}_T^2 + \hat{\sigma}_C^2 + (1 - \delta)^2 \hat{\sigma}_P^2}}$$
 and z_* is the 97.5 quantile of the standard normal distribution.

6.3.4. Subgroup Analyses for Key Secondary Efficacy Endpoints

Subgroup analyses comparing each filgotinib dose group to the placebo group will be performed at Week 12 and Week 24 for the key secondary efficacy endpoints, for the subgroups specified in Section 3.4.

The subgroup analysis for the proportion of subjects who achieve DAS28(CRP) < 2.6 will be performed using the Fisher's exact test based on the NRI method. The number and percentage of subjects with DAS28(CRP) < 2.6 will be provided for each treatment group within the subgroups.

The change from Baseline in HAQ-DI will be analyzed using the MMRM method that includes data at postbaseline visits up to the time point of interest with baseline value, treatment, visit, and treatment by visit as fixed effects and subjects being the random effect. The LS mean, LS mean difference, SE and 95% CI will be presented. The change from Baseline in mTSS, change from Baseline in SF-36 PCS and change from Baseline in FACIT-Fatigue will be analyzed similarly using the MMRM model, respectively. Descriptive statistics for actual values and change from baseline will also be presented for each treatment group within the subgroups.

6.4. Other Secondary Efficacy Endpoints

Other secondary efficacy endpoints include:

- The proportion of subjects who achieve ACR50 and ACR70 at Weeks 4, 12, 24 and 52, ACR20 at Weeks 4, 24, and 52, and ACR20/50/70 over time from Day 1 through Week 52
- Change from Baseline in individual components of the ACR response at Weeks 4, 12, 24, and 52 and over time from Day 1 through Week 52
- The proportion of subjects who achieve decrease in HAQ-DI of ≥ 0.22 at Weeks 4, 12, 24, and 52, and over time from Day 1 through Week 52
- Change from Baseline in DAS28(CRP) at Weeks 4, 12, 24, and 52, and over time from Day 1 through Week 52
- The proportion of subjects who achieve DAS28(CRP) ≤ 3.2 at Weeks 4, 24, and 52, and over time from Day 1 through Week 52
- The proportion of subjects who achieve DAS28(CRP) < 2.6 at Weeks 4, 24, and 52, and over time from Day 1 through Week 52

- ACR-N and EULAR response at Weeks 4, 12, 24, and 52, and over time from Day 1 through Week 52
- Change from Baseline in Clinical Disease Activity Index (CDAI) at Weeks 4, 12, 24, and 52, and over time from Day 1 through Week 52
- Change from Baseline in Simplified Disease Activity Index (SDAI) at Weeks 4, 12, 24, and 52, and over time from Day 1 through Week 24
- Change from Baseline in mTSS at Week 52
- The proportion of subjects with no radiographic progression from Baseline at Week 24 and 52
- Absolute value and change from Baseline in SF-36, FACIT-Fatigue, and the EQ-5D over time at Weeks 4, 12, 24 (except for SF-36 PCS and FACIT-Fatigue) and 52, and over time from Day 1 through Week 52
- Absolute value and change from Baseline in WPAI-RA at Weeks 4, 12, 24, and 52, and over time from Day 1 through Week 52

6.4.1. Definition of Other Secondary Efficacy Endpoints

6.4.1.1. ACR50 and ACR70

ACR50 and ACR70 are similarly defined as ACR20 (see Section 6.2.1), except that the improvement threshold from Baseline is 50% and 70%, respectively.

6.4.1.2. SDAI and CDAI

Simplified Disease Activity Index (SDAI) is a composite measure that sums the TJC28, SJC28, the SGA on a 0-10 scale, the PGA on a 0-10 scale, and the hsCRP (in mg/dL). SDAI is scored as follows {Aletaha 2005}:

$$\text{SDAI} = \text{TJC28} + \text{SJC28} + \text{SGA} + \text{PGA} + \text{CRP}$$

Higher SDAI score indicates more severe disease activity status.

Clinical Disease Activity Index (CDAI) is a further simplification of the SDAI that excludes the CRP, which is calculated using the following formula {Aletaha 2005}:

$$\text{CDAI} = \text{TJC28} + \text{SJC28} + \text{SGA} + \text{PGA}$$

CDAI can range from 0 to 76, with higher score indicating more severe disease activity status.

No component-level imputation will be performed for the calculation of both SDAI and CDAI. If any components are missing, the SDAI and CDAI will be set as missing.

6.4.1.3. ACR-N

ACR-N is defined as the smallest percentage improvement from baseline in swollen joints, tender joints and the median of the following 5 items (PGA, SGA, subject’s pain assessment, HAQ-DI score and CRP). It has a range between 0 and 100%. In particular,

ACR-N = min {improvement in TJC68 (%), improvement in SJC66 (%), median [improvement in SGA (%), improvement in PGA (%), improvement in pain assessment (%), improvement in HAQ-DI (%), improvement in hsCRP (%)]}.

If this calculation results in a negative value, then the ACR-N is set to 0. If any components are missing, the ACR-N will be set as missing.

6.4.1.4. EULAR response

Subject’s response will be categorized according to the following table based on the DAS28(CRP).

Table 6-2. EULAR Response Criteria

DAS28(CRP) at Visit	DAS28(CRP) Improvement from Baseline		
	> 1.2	> 0.6 and 1.2	0.6
3.2	Good Response	Moderate Response	No Response
> 3.2 and 5.1	Moderate Response	Moderate Response	No Response
> 5.1	Moderate Response	No Response	No Response

6.4.1.5. European Quality of Life 5 Dimensions – 5 Levels (EQ-5D-5L)

The EQ-5D-5L is a standardized measure of health status of the subject at the visit (same day) that provides a simple, generic measure of health for clinical and economic appraisal. The EQ-5D-5L consists of 2 components: a descriptive system of the subject’s health and a rating of his or her current health state using a 0 to 100 VAS. The descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The subject is asked to indicate his/her health state by ticking (or placing a cross) in the box associated with the most appropriate statement in each of the 5 dimensions. The VAS records the subject’s self-rated health on a vertical VAS in which the endpoints are labeled “best imaginable health state” on the top and “worst imaginable health state” on the bottom. Higher EQ VAS indicates better health. The EQ-5D-5L will be scored according to the developer’s instructions (scoring guidelines).

6.4.1.6. Work Productivity and Activity Impairment questionnaire (WPAI)– RA

The WPAI is a questionnaire developed to measure impairments in work activities in subjects with RA. The questionnaire consists of 6 questions:

- Q1: currently employed,
- Q2: work time missed due to RA,
- Q3: work time missed due to other reasons,
- Q4: hours actually worked,
- Q5: degree RA affected productivity while working (0-10 VAS; with 0 indicating no effect and 10 indicating RA completely prevented the subject from working),
- Q6: degree RA affected productivity in regular unpaid activities (0-10 VAS; with 0 indicating no effect and 10 indicating RA completely prevented the subject's daily activities).

The recall period for questions 2 to 6 is 7 days. WPAI-RA outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, that is, worse outcomes, as follows:

- Absenteeism (work time missed) due to RA: $100 \times \{Q2 / (Q2 + Q4)\}$
- Presenteeism (impairment while working) due to RA: $100 \times \{Q5 / 10\}$
- Work productivity loss (overall work impairment) due to RA: $100 \times \{Q2 / (Q2 + Q4) + [(1 - Q2 / (Q2 + Q4)) \times (Q5 / 10)]\}$
- Activity impairment due to RA: $100 \times \{Q6 / 10\}$

If Question 1 (Are you currently employed?) is 'NO', then only the activity impairment score can be determined.

6.4.1.7. Healthcare Resource Utilization Questionnaire

The Healthcare Resource Utilization Questionnaire (HRUQ) is designed to assess healthcare usage during the previous three months across a number of direct medical cost domains.

6.4.1.8. Treatment Satisfaction Questionnaire for Medication (TSQM)

TSQM Scale scores are computed by adding the items loading on each factor. The lowest possible score is subtracted from this composite score and divided by the greatest possible score minus the lowest possible score. This provides a transformed score between 0 and 1 that should be multiplied by 100. Note that only one item may be missing from each scale before the subscale should be considered invalid for that respondent. Detailed scoring method is available in the Quintiles TSQM Scoring Manual v1.4.

6.4.1.9. Exploratory PRO

Subjects will be asked to rate the effect of their RA on their sexual functioning using a 0-100 VAS, with 0 indicating “rheumatoid arthritis has no effect on my sexual function” and 100 indicating “rheumatoid arthritis completely inhibits my sexual function”.

6.4.2. Analysis Methods for Other Secondary Efficacy Endpoints

The FAS will be used for all summaries and analyses of other secondary efficacy endpoints. Statistical testing will be performed up to Week 24. The nominal p-values will be presented, if applicable. No formal statistical testing will be performed after Week 24, unless otherwise specified.

The proportion of subjects who achieve ACR20/50/70, and proportion of subjects with change in HAQ-DI ≥ 0.22 (ie, reduction in HAQ-DI ≥ 0.22), DAS28(CRP) ≤ 3.2 or DAS28(CRP) < 2.6 , will be analyzed using the same logistic regression method with NRI as the primary endpoint analysis described in Section 6.2.3. Comparison will be made between each filgotinib dose group and placebo group. The 2-sided 95% CIs for the proportion based on normal approximation with the sample variance will be provided for each treatment group and visit. In addition, non-stratified response rate difference along with its 95% CI calculated based on the normal approximation with the pooled sample variance will be provided. The OC and LOCF values will be analyzed as a sensitivity approach to the primary method that uses NRI.

The proportion of subjects having no radiographic progression as defined by change from baseline in mTSS ≥ 0.5 at Week 24 will be analyzed using the same logistic regression method based on the OC. Comparison will be made between each filgotinib dose group and placebo group. The 2 sided 95% CIs for the proportion based on normal approximation with the sample variance will be provided for each treatment group. In addition, non-stratified response rate difference along with its 95% CI calculated based on the normal approximation with the pooled sample variance will be provided. The no radiographic progression as defined by change from baseline in mTSS ≥ 0 , and the smallest detectable change (SDC) at Week 24 will also be analyzed using the logistic regression method based on the OC. SDC is the smallest detectable change computed from the variability in change from baseline in mTSS of the two imaging assessors {Bruynesteyn 2005}.

The change from Baseline in DAS28(CRP), CDAI, SDAI and mTSS will be analyzed using MMRM method that includes data at postbaseline visits up to the time point of interest. The MMRM models will include baseline value, stratification factors, treatment, visit, and treatment by visit interaction as fixed effects and subject being the random effect. The MMRM model will include all treatment groups. An unstructured variance-covariance matrix will be used. The Kenward-Roger method will be used to estimate the degrees of freedom. Missing change scores due to missing study visits or early withdrawal will not be otherwise imputed using the MMRM approach. The LS means and 95% CI of the difference in mean change scores from Baseline in DAS28(CRP), CDAI, SDAI and mTSS between each filgotinib dose group and placebo group from the MMRM model will be provided for each postbaseline visit. Descriptive statistics of actual and change in DAS28(CRP), CDAI, SDAI and mTSS from baseline to postbaseline visits will also be provided by treatment group and visit.

Actual values and change from Baseline in individual components of the ACR response (including TJC68, SJC66, SGA, PGA, Subject's pain assessment, and hsCRP), TJC28 and SJC28 will be summarized using descriptive statistics (sample size, mean, SD, median, Q1, Q3, minimum, and maximum) by treatment group and visit. In addition, the MMRM model with baseline value, stratification factors, treatment, visit and treatment and visit interaction as fixed effects and subject being the random effect will be performed to compare each filgotinib dose group to placebo control group. The LS means and 95% CI of the difference between each filgotinib dose group and placebo control group will be provided.

Actual values of ACR-N will be summarized using descriptive statistics (sample size, mean, SD, median, Q1, Q3, minimum, and maximum) by treatment and visit.

Number and percentage of subjects for EULAR responses will be presented for each visit by treatment.

For HRQoL endpoints, the analysis methods are detailed below:

- **SF-36**

The transformed scores and change from baseline in 8 domains and 2 summary component scores (PCS and MCS) of the SF-36 will be summarized at each visit by treatment group using descriptive statistics (sample size, mean, SD, median, Q1, Q3, minimum and maximum).

The change from Baseline in PCS and MCS will be analyzed using MMRM method that includes data at postbaseline visits up to the time point of interest, without imputation for missing data. The MMRM models will be used to evaluate treatment effect on change score from Baseline, with baseline value, stratification factors, treatment, visit, and treatment by visit interaction included as fixed effects and subject being the random effect. An unstructured variance-covariance matrix will be used. The Kenward-Roger method will be used to estimate the degrees of freedom. To test for a treatment difference between each filgotinib dose group and placebo, the LS means along with the 95% CIs of the difference from MMRM, and p-value will be provided for each postbaseline visit.

- **FACIT-Fatigue**

The change from baseline in FACIT-Fatigue scale score will be analyzed using similar MMRM models as for SF-36. To test for a treatment difference between each filgotinib dose group and placebo, LS mean difference along with 95% CI and p-values will be presented for each postbaseline visit. Missing change scores due to missing study visits or early withdrawal will not be otherwise imputed using the MMRM approach. Summary statistics of the actual score and change from baseline in FACIT-Fatigue scale score will also be displayed by treatment and visit.

- **EQ-5D-5L**

Summary statistics of two outcomes of the EQ-5D-5L described as the following will be provided:

- A health profile: the number and percentage of subjects at each categorical response for the 5 dimensions (mobility, self-care, usual activity, pain/discomfort, and anxiety/depression) will be provided by treatment and visit.
- A self-perceived current health score: calculated from subject level EQ VAS responses (continuous variable). Descriptive statistics (sample size, mean, SD, min, median, and max) will be provided by treatment and visit.

The change from baseline in EQ VAS score will be analyzed using similar MMRM models as for SF-36. To test for a treatment difference between each filgotinib dose group and placebo, LS mean difference, 95% CI and p-values will be presented. Missing change scores due to missing study visits or early withdrawal will not be otherwise imputed using the MMRM approach.

- **WPAI – RA**

Summary statistics of the actual scores and change from baseline in each of the four types of scores of WPAI-RA (absenteeism, presenteeism, work productivity loss, and activity impairment) will be summarized by treatment and visit using descriptive statistics (sample size, mean, SD, median, Q1, Q3, minimum and maximum).

The analyses of absenteeism, presenteeism, and work productivity loss will be based on subjects employed at both baseline and postbaseline visits.

- **HRUQ**

Summary statistics will be provided for all the following parameters by treatment group and visit.

Healthcare resource utilization – Outpatient visits:

— Number and percentage of subjects with any medical visits, and the number of visits related to RA will be provided for the categories:

Outpatient Healthcare Provider

Emergency Room

Chiropractor, Physical or Occupational Therapist

Healthcare resource utilization – Inpatient hospitalization:

— Number and percentage of subject with hospital stays, and number of stays related to RA

— Descriptive statistics for the total number of days in hospital related to RA

— Number and percentage of subject with nursing home or rehabilitation center stays, and number of stays related to RA

— Descriptive statistics for the total number of days in nursing home or rehabilitation center related to RA

- **TSQM**

Descriptive statistics of the scores from each of the 4 domains (Effectiveness, Side Effects, Convenience, and Global Satisfaction) will be presented by treatment group and by visit.

- **Exploratory PRO**

Summary statistics of the actual score and change from baseline will be displayed by treatment and visit. Subjects who marked ‘prefer not to answer’ will not be included in this analysis.

Plots of proportions of subjects for categorical endpoints and mean \pm SD for continuous endpoints (including each individual component of the ACR response) will be presented over time by treatment.

Additional statistical tests will be performed for the following efficacy endpoints;

- Compare each filgotinib dose group with adalimumab group at week 24 and 52 in proportion of subjects achieving ACR20, DAS28(CRP) ≥ 3.2 and DAS28(CRP) < 2.6 using similar logistic regression as described in Section 6.2.3, and in change from baseline in HAQ-DI, SF-36 PCS and FACIT-Fatigue using similar MMRM model as described in Section 6.3.2.

- Compare filgotinib 200 mg group with placebo switching to filgotinib 200 mg group, and filgotinib 100 mg group with placebo switching to filgotinib 100 mg group at Week 52 in change from baseline in mTSS using similar MMRM model as described in Section 6.3.2.
- Compare filgotinib 200 mg group with placebo switching to filgotinib 200 mg group, and filgotinib 100 mg group with placebo switching to filgotinib 100 mg group at Week 52 in the proportion of subjects having no radiographic progression using similar logistic regression method as described in Section 6.4.2.

6.5. Changes From Protocol-Specified Efficacy Analyses

The following changes were made from the protocol-specified efficacy analyses:

- It has been observed from the blinded data that the enrollment rate is low in some combinations of stratification factors, which will result in the small cell counts for the stratified Cochran-Mantel-Haenszel test adjusted for the stratification factors. The logistic regression analysis with treatment and stratification factors in the model will be used instead to analyze binary endpoints.
- The following endpoints have been updated as key secondary efficacy endpoints in Section 6.3.1 and included in the hierarchy testing in Section 3.5, in order to support inclusion in the label.
 - Change from baseline in SF-36 physical component summary (PCS) at Week 12
 - Change from baseline in FACIT-Fatigue at Week 12
- Given the importance of determining the lowest effective dose for filgotinib in RA, the hierarchical ordering has been updated in Section 3.5 to test filgotinib 100 mg immediately after each test for filgotinib 200 mg (including the primary endpoint and each of the key secondary endpoints).
- Given the importance of achieving very low disease activity $\text{DAS28(CRP)} < 2.6$ in RA therapy, the testing for comparison of filgotinib with placebo on $\text{DAS28(CRP)} < 3.2$ is removed from the hierarchy list, and the testing for comparison of filgotinib with adalimumab on $\text{DAS28(CRP)} < 2.6$ at week 12 is added to the hierarchy list. In addition, the comparison of filgotinib with placebo on $\text{DAS28(CRP)} < 2.6$ is evaluated at Week 12 prior to the specified non-responder assessment and start of standard of care therapy at Week 14.

7. SAFETY ANALYSES

7.1. Adverse Events and Deaths

7.1.1. Adverse Event Dictionary

Clinical and laboratory adverse events (AEs) will be coded using the MedDRA 21.0. System organ class (SOC), high-level group term (HLGT), high-level term (HLT), preferred term (PT), and lower-level term (LLT) will be provided in the AE dataset.

7.1.2. Adverse Event Severity

Adverse events are graded by the investigator as Grade 1, 2, 3, 4, or 5 according to toxicity criteria specified in the protocol. The severity grade of events for which the investigator did not record severity will be categorized as “missing” for tabular summaries and data listings. The missing category will be listed last in summary presentation.

7.1.3. Relationship of Adverse Events to Study Drug

Related AEs are those for which the investigator selected “Related” on the AE CRF to the question of “Related to Study Treatment.” Relatedness will always default to the investigator’s choice, not that of the Medical Monitor. Events for which the investigator did not record relationship to study drug will be considered related to study drug for summary purposes. However, by-subject data listings will show the relationship as missing.

7.1.4. Serious Adverse Events

Serious adverse events (SAEs) will be identified and captured as SAEs if AEs met the definitions of SAE that were specified in the study protocol. SAEs captured and stored in the clinical database will be reconciled with the SAE database from the Gilead Pharmacovigilance & Epidemiology Department (PVE) before data finalization.

7.1.5. Treatment-Emergent Adverse Events

7.1.5.1. Definition of Treatment-Emergent Adverse Events

Treatment-emergent adverse events (TEAEs) are defined as one or both of the following:

- Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug
- Any AEs leading to premature discontinuation of study drug

For placebo subjects who were then re-randomized, TEAEs with an onset date prior to the first dose date of filgotinib will be allocated to the placebo controlled period. TEAEs with an onset date on or after the first dose date of filgotinib will be allocated to the re-randomized period.

7.1.5.2. Incomplete Dates

If the onset date of the AE is incomplete and the AE stop date is not prior to the first dosing date of study drug, then the month and year (or year alone if month is not recorded) of onset determine whether an AE is treatment emergent. The event is considered treatment emergent if both of the following 2 criteria are met:

- The AE onset is the same as or after the month and year (or year) of the first dosing date of study drug, and
- The AE onset date is the same as or before the month and year (or year) of the date corresponding to 30 days after the date of the last dose of study drug

An AE with completely missing onset and stop dates, or with the onset date missing and a stop date later than the first dosing date of study drug, will be considered to be treatment emergent. In addition, an AE with the onset date missing and incomplete stop date with the same or later month and year (or year alone if month is not recorded) as the first dosing date of study drug will be considered treatment emergent.

For placebo subjects who were then re-randomized, an AE with incomplete onset date that is prior to the month and year (or year) of the first dose date of filgotinib will be allocated to the placebo controlled period. An AE with incomplete onset date that is after the month and year (or year) of the first dose date of filgotinib will be allocated to the re-randomized period.

In addition, an AE with completely missing onset date or incomplete onset date that is same as the month and year (or year) of the first dose date of filgotinib, and stop date that is prior to the date (or month and year if day is not recorded; or year alone if month is not recorded) of the first dose of filgotinib will be allocated to the placebo controlled period. An AE with completely missing onset date or incomplete onset date that is same as the month and year (or year) of the first dose date of filgotinib, and stop date that is missing, or the same as, or after the date (or month and year if day is not recorded; or year alone if month is not recorded) of the first dose of filgotinib will be allocated to the re-randomized period.

7.1.6. Summaries of Adverse Events and Deaths

Treatment-emergent AEs will be summarized based on the Safety Analysis Set.

7.1.6.1. Summaries of AE incidence in Combined Severity Grade Subsets

The number and percentage of subjects who experienced at least 1 TEAE will be provided and summarized by SOC, HLT, PT, and treatment group. For other AEs described below, summaries will be provided by SOC, PT, and treatment group:

- TEAEs of Grade 3 or higher (by maximum severity)

- TEAEs of Grade 2 or higher
- All TE treatment-related AEs
- TE Treatment-related AEs of Grade 3 or higher (by maximum severity)
- TE Treatment-related AEs of Grade 2 or higher
- All TE SAEs
- All TE treatment-related SAEs
- All TEAEs leading to premature discontinuation of any study drug
- All TEAEs leading to premature discontinuation of study
- All TE SAEs leading to death (ie, outcome of death)
- All TEAEs leading to temporary interruption of any study drug

A brief, high-level summary of AEs described above will be provided by treatment group and by the number and percentage of subjects who experienced the above AEs. All deaths observed in the study will be also included in this summary.

Multiple events will be counted only once per subject in each summary. Adverse events will be summarized and listed first in alphabetic order of SOC and HLT within each SOC (if applicable), and then by PT in descending order of total frequency within each SOC. For summaries by severity grade, the most severe grade will be used for those AEs that occurred more than once in an individual subject during the study.

In addition to the above summary tables, all TEAEs and TE treatment-related AEs will be summarized by PT only, in descending order of total frequency.

In addition, data listings will be provided for the following:

- All AEs, indicating whether the event is treatment emergent
- All AEs of Grade 3 or higher
- All AEs of Grade 2 or higher
- SAEs
- Deaths
- All SAEs leading to death (ie, outcome of death)

- AEs leading to premature discontinuation of any study drug
- AEs leading to premature discontinuation of study
- AEs leading to temporary interruption of any study drug

7.1.7. Adverse Events of Special Interest

Events of interest will be identified by the use of either SMQs or MSTs. However, should additional cases not detected by the predefined search term listings be identified during the clinical review process, these cases will also be reported by respective category.

7.1.7.1. Adjudication Committee for MACE

An independent cardiovascular safety endpoint adjudication committee (CVEAC) will be formed to periodically review and adjudicate all potential major adverse cardiovascular events (MACE) events. MACE events are defined as cardiovascular death, non-fatal myocardial infarction and non-fatal stroke.

To identify the MACE, the following potential cases identified using MedDRA search term (MST) searches will be adjudicated:

- All deaths
- Cardiovascular events (meeting serious criteria)
- Myocardial infarction (Narrow)
- Hospitalization for unstable angina
- Transient ischemic attack
- Stroke
- Hospitalization for cardiac failure
- Percutaneous coronary intervention

The CVEAC will review those potential MACE and related clinical data to determine whether a MACE has developed. The CVEAC's role and responsibilities and the data to be provided to the CVEAC are described in a mutually agreed upon CVEAC charter. The CVEAC charter defines the CVEAC membership, adjudication process, meeting logistics, and meeting frequency.

The number and percentage of subjects with positively adjudicated MACE will be summarized by treatment group using the PT.

A by-subject listing for all subjects who have potential MACE and who have a positively adjudicated MACE at any time will be provided.

7.1.7.2. Other Adverse Events of Special Interest

In addition to general safety parameters and MACE, safety information on other adverse events of special interest (AESIs) will also be analyzed. AESIs will be identified by laboratory results, standardized MedDRA queries (SMQs), sponsor defined MSTs, or a combination of these methods as indicated below.

- All infections (defined as all PTs in the Infections and Infestations SOC)
- Serious infections (defined as all PTs in the Infections and Infestations SOC that are SAEs)
- Infections of special interest as defined below
 - a) Herpes zoster
 - b) Active tuberculosis
 - c) Opportunistic infections
 - d) Hepatitis B or C infections
- Deep vein thrombosis (DVT) and pulmonary embolism (PE)
- Malignancy (including lymphoma; not including nonmelanoma skin cancer)
- Nonmelanoma skin cancer
- Gastrointestinal (GI) perforations

The number and percentage of subjects with aforementioned events of special interest will be provided by the PT for each AE of special interests.

A by-subject listing for all subjects having AE of special interests at any time will be provided for each AE of special interest.

7.1.8. Additional Analysis for Adverse Events

The number and proportion of subjects who experienced at least one treatment-emergent SAE, or one treatment-emergent AE of special interests will be summarized by treatment group. The comparisons of the proportions between the placebo group during placebo controlled period and the filgotinib treatment groups will be performed. The 2-sided 95% CI of the proportion based on normal approximation with the sample variance will be provided for each treatment group. In addition, the difference in proportions between treatment groups with its 95% CI based on the normal approximation with the pooled sample variance will be provided.

7.2. Laboratory Evaluations

Laboratory data collected during the study will be analyzed and summarized using both quantitative and qualitative methods. Summaries of laboratory data will be provided for the Safety Analysis Set and will include data collected up to the last dose of any study drug plus 30 days for subjects who have permanently discontinued study drug, or all available data at the time of the database snapshot for subjects who were ongoing at the time of an interim analysis. The analysis will be based on values reported in conventional units. When values are below the LOQ, they will be listed as such, and the closest imputed value will be used for the purpose of calculating summary statistics as specified in Section 3.7.

A baseline laboratory value will be defined as the last nonmissing measurement obtained on or prior to the date/time of first dose of any study drug.

For placebo subjects who were then re-randomized, the baseline laboratory value for the re-randomization period will be the last available measurement obtained on or prior to the date/time of first dose of filgotinib. The lab abnormalities after the first dose of filgotinib will be assessed from the baseline of the re-randomization period.

A by-subject listing for laboratory test results will be provided by subject ID number and visit in chronological order for hematology, serum chemistry, and urinalysis separately. Values falling outside of the relevant reference range and/or having a severity grade of 1 or higher on the CTCAE severity grade will be flagged in the data listings, as appropriate.

No formal statistical testing is planned.

7.2.1. Summaries of Numeric Laboratory Results

Descriptive statistics of Baseline values, values at each postbaseline visit and change from Baseline at each postbaseline visit will be provided by treatment group for the following laboratory tests:

- Hematology
 - Hematocrit
 - Hemoglobin
 - Platelet count
 - Red blood cell count
 - White blood cell (WBC) count
 - Mean corpuscular volume
 - Lymphocytes

- Monocytes
- Neutrophils
- Eosinophils
- Basophils
- Chemistry
 - Alanine aminotransferase (ALT)
 - Aspartate aminotransferase (AST)
 - Alkaline phosphatase (ALP)
 - Total bilirubin
 - Serum creatinine
 - Creatinine clearance by Cockcroft-Gault formula
 - Creatinine phosphokinase (CPK)
 - Glucose
- Lipid
 - Triglycerides
 - Total cholesterol
 - HDL
 - LDL
 - LDL/HDL ratio

Change from baseline to a postbaseline visit will be defined as the visit value minus the baseline value. The mean, median, Q1, Q3, minimum, and maximum values will be displayed to the reported number of digits; SD values will be displayed to the reported number of digits plus 1.

Median (Q1, Q3) of the observed values for the laboratory tests specified above will be plotted using a line plot by treatment group and visit.

In the case of multiple values in an analysis window, data will be selected for analysis as described in Section 3.8.3.

7.2.2. Graded Laboratory Value

The CTCAE Version 4.03 will be used to assign toxicity grades (0 to 4) to laboratory results for analysis. Grade 0 includes all values that do not meet the criteria for an abnormality of at least Grade 1. For laboratory tests with criteria for both increased and decreased levels, analyses for each direction (ie, increased, decreased) will be presented separately.

7.2.2.1. Treatment-Emergent Laboratory Abnormalities

Treatment-emergent laboratory abnormalities are defined as values that increase at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of last dose of any study drug plus 30 days for subjects who permanently discontinued study drug, or the last available date in the database snapshot for subjects who were still on treatment at the time of an interim analysis.

For placebo subjects who were then re-randomized, treatment-emergent laboratory abnormalities of placebo period are defined as values that increase at least 1 toxicity grade from the baseline at any postbaseline time point, up to and including the first dose date of filgotinib. Treatment-emergent laboratory abnormalities of re-randomized period are defined as values that increase at least 1 toxicity grade from the new baseline after Week 24 at any postbaseline time point, up to and including the date of last dose of any study drug plus 30 days, or the last available date in the database snapshot for subjects who were still on treatment at the time of an interim analysis.

Placebo subjects who were not re-randomized have treatment-emergent laboratory abnormalities in the placebo period which are defined as values that increase 1 toxicity grade from the baseline at any postbaseline time point, up to and including the date of last dose of any study drug plus 30 days.

If the relevant baseline laboratory value is missing, any abnormality of at least Grade 1 observed within the time frame specified above will be considered treatment emergent.

7.2.2.2. Treatment-Emergent Marked Laboratory Abnormalities

Treatment-emergent marked laboratory abnormalities are defined as values that increase from baseline by at least 3 toxicity grades at any postbaseline time point, up to and including the date of the last dose of any study drug plus 30 days for subjects who permanently discontinued study drug or the last available date in the database snapshot for subjects who were still on treatment at the time of an interim analysis.

For placebo subjects who were then re-randomized, treatment-emergent marked laboratory abnormalities of placebo period are defined as values that increase from baseline by at least 3 toxicity grades at any postbaseline time point, up to and including the first dose date of filgotinib. Treatment-emergent marked laboratory abnormalities of re-randomized period are defined as values that increase from the new baseline after Week 24 by at least 3 toxicity grades at any postbaseline time point, up to and including the date of last dose of any study drug plus 30 days, or the last available date in the database snapshot for subjects who were still on treatment at the time of an interim analysis.

Placebo subjects who were not re-randomized have treatment-emergent marked laboratory abnormalities in the placebo period which are defined as values that increase from baseline by at least 3 toxicity grades at any postbaseline time point, up to and including the date of last dose of any study drug plus 30 days.

If the relevant baseline laboratory value is missing, any Grade 3 or higher values observed within the time frame specified above will be considered treatment-emergent marked abnormalities.

7.2.2.3. Summaries of Laboratory Abnormalities

Laboratory data that are categorical will be summarized using the number and percentage of subjects in the study with the given response at baseline and each scheduled postbaseline visit.

The following summaries (number and percentage of subjects) for treatment-emergent laboratory abnormalities will be provided by laboratory test and treatment group; subjects will be categorized according to the most severe postbaseline abnormality grade for a given laboratory test:

- Graded laboratory abnormalities
- Grade 3 or higher laboratory abnormalities
- Marked laboratory abnormalities

For all summaries of laboratory abnormalities, the denominator is the number of subjects with nonmissing postbaseline values up to 30 days after last dosing date.

A by-subject listing of treatment-emergent Grade 3 or higher laboratory abnormalities and marked laboratory abnormalities will be provided separately by subject ID number and visit in chronological order. These listings will include all test results that were collected throughout the study for the laboratory test of interest, with all applicable severity grades or abnormal flags displayed.

7.2.3. Laboratory Evaluations of Special Interest

7.2.3.1. Liver-Related Laboratory Evaluations

Liver-related abnormalities after initial study drug dosing will be examined and summarized using the number and percentage of subjects who were reported to have the following laboratory test values for postbaseline measurements:

- AST: (a) > 3 times of the upper limit of reference range (ULN); (b) > 5 x ULN; (c) > 10 x ULN; (d) > 20 x ULN
- ALT: (a) > 3 x ULN; (b) > 5 x ULN; (c) > 10 x ULN; (d) > 20 x ULN
- AST or ALT > 3 x ULN and total bilirubin > 2 x ULN

The summary will include data from all postbaseline visits up to 30 days after the last dose of any study drug. For individual laboratory tests, subjects will be counted once based on the most severe postbaseline values. For both the composite endpoints of AST or ALT and total bilirubin, subjects will be counted once when the criteria are met at the same postbaseline visit date. The denominator is the number of subjects in the Safety Analysis Set who have nonmissing postbaseline values of all relevant tests at the same postbaseline visit date. A listing of subjects who met at least 1 of the above criteria will be provided.

7.2.3.2. Complete Blood Count-Related Laboratory Evaluations

Complete blood count (CBC)-related abnormalities such as anemia, leucopenia, neutropenia, lymphopenia, and thrombocytopenia after initial study drug dosing will be examined and summarized using the number and percentage of subjects who were reported to have the following laboratory test values for postbaseline measurements:

- Hemoglobin: (a) any postbaseline worsening CTCAE grade from baseline; (b) baseline value of less than Grade 3 and increase to Grade 3 or higher at worst postbaseline; (c) baseline value of less than Grade 3 and increase to Grade 4 at worst postbaseline
- WBC count: (a) any postbaseline worsening CTCAE grade from baseline; (b) baseline value of less than Grade 3 and increase to Grade 3 or higher at worst postbaseline; (c) baseline value of less than Grade 3 and increase to Grade 4 at worst postbaseline
- Absolute neutrophil count: (a) any postbaseline worsening CTCAE grade from baseline; (b) baseline value of less than Grade 3 and increase to Grade 3 or higher at worst postbaseline; (c) baseline value of less than Grade 3 and increase to Grade 4 at worst postbaseline

- Lymphocyte count: (a) any postbaseline worsening CTCAE grade from baseline; (b) baseline value of less than Grade 3 and increase to Grade 3 or higher at worst postbaseline; (c) baseline value of less than Grade 3 and increase to Grade 4 at worst postbaseline
- Platelet count: (a) any postbaseline worsening CTCAE grade from baseline; (b) baseline value of less than Grade 3 and increase to Grade 3 or higher at worst postbaseline; (c) baseline value of less than Grade 3 and increase to Grade 4 at worst postbaseline

The summary will include data from all postbaseline visits up to 30 days after the last dose of any study drug.

7.3. Body Weight and Vital Signs

Descriptive statistics will be provided by treatment group for body weight, BMI and vital signs (systolic and diastolic blood pressures [mmHg], pulse [beats/min]) as follows:

- Baseline value
- Values at each postbaseline visit
- Change from baseline at each postbaseline visit

A baseline value will be defined as the last available value collected on or prior to the date/time of first dose of any study drug.

For placebo subjects who were then re-randomized, the baseline value for re-randomization period will be defined as the last available value collected on or prior to the date/time of the first dose of filgotinib.

Change from baseline to a postbaseline visit will be defined as the postbaseline value minus the baseline value. Body weight and vital signs measured at unscheduled visits will be included for the baseline value selection.

In the case of multiple values in an analysis window, data will be selected for analysis as described in Section 3.8.3. No formal statistical testing is planned.

A by-subject listing of vital signs (systolic and diastolic blood pressure [mmHg], pulse [beats/min], respiration [breaths/min], and body temperature [°C]) will be provided by subject ID number and visit in chronological order. In the same manner, a by-subject listing of body weight, height, and BMI will be provided separately.

7.4. Prior and Concomitant Medications

Medications collected at screening and during the study will be coded using the World Health Organization (WHO) Drug dictionary version BSEP17.

All the analyses in this section will be performed for general prior /concomitant medications and RA-specific prior/concomitant medications separately, unless otherwise specified.

7.4.1. Prior Medications

Prior medications are defined as any medication taken before a subject took the first study drug.

Prior medications will be summarized by Anatomical Therapeutic Chemical (ATC) drug class preferred name using the number and percentage of subjects for each treatment group and overall. A subject reporting the same medication more than once will be counted only once when calculating the number and percentage of subjects who received that medication. The summary will be provided by preferred name in order of descending overall frequency. For drugs with the same frequency, sorting will be done alphabetically.

For the purposes of analysis, any medication with a start date prior to the first dosing date of any study drug will be included in the prior medication summary regardless of when the stop date is. If a partial start date is entered the medication will be considered prior unless the month and year (if day is missing) or year (if day and month are missing) of the start date are after the first dosing date. Medications with a completely missing start date will be included in the prior medication summary, unless otherwise specified.

Summaries will be based on the Safety Analysis Set. No formal statistical testing is planned.

7.4.2. Concomitant Medications

Concomitant medications are defined as medications taken while a subject took study drug. Use of concomitant medications will be summarized by ATC drug class preferred name using the number and percentage of subjects for each treatment group. A subject reporting the same medication more than once will be counted only once when calculating the number and percentage of subjects who received that medication. The summary will be provided by preferred term in descending overall frequency. For drugs with the same frequency, sorting will be done alphabetically.

For the purposes of analysis, any medication with a start date prior to or on the first dosing date of any study drug and continued to take after the first dosing date, or started after the first dosing date but prior to or on the last dosing date of study drug will be considered concomitant medications. Medications started and stopped on the same day as the first dosing date or the last dosing date of any study drug will also be considered concomitant. Medications stopped on the same day as the first dosing date will be considered concomitant. Medications with a stop date prior to the date of first dosing date of any study drug or a start date after the last dosing date of any study drug will be excluded from the concomitant medication summary. If a partial stop date is entered, any medication with the month and year (if day is missing) or year (if day and month are missing) prior to the date of first study drug administration will be excluded from the concomitant medication summary. If a partial start date is entered, any medication with the month and year (if day is missing) or year (if day and month are missing) after the study drug stop date will be excluded from the concomitant medication summary. Medications with completely missing start and stop dates will be included in the concomitant medication summary, unless otherwise specified.

For placebo subjects who were then re-randomized, concomitant medication with a start date prior to the first dose date of filgotinib will be allocated to the placebo controlled period. Concomitant medication with a start date on or after first dose date of filgotinib will be allocated to the re-randomized period.

For placebo subjects who were then re-randomized, a concomitant medication with incomplete start date that is prior to the month and year (or year) of the first dose date of filgotinib will be allocated to the placebo controlled period. A concomitant medication with incomplete start date that is after the month and year (or year) of the first dose date of filgotinib will be allocated to the re-randomized period.

In addition, an concomitant medication with completely missing start date or incomplete start date that is same as the month and year (or year) of the first dose date of filgotinib, and stop date that is prior to the date (or month and year if day is not recorded; or year alone if month is not recorded) of the first dose of filgotinib will be allocated to the placebo controlled period. An concomitant medication with completely missing start date or incomplete start date that is same as the month and year (or year) of the first dose date of filgotinib, and stop date that is missing, or the same as, or after the date (or month and year if day is not recorded; or year alone if month is not recorded) of the first dose of filgotinib will be allocated to the re-randomized period

Summaries will be based on the Safety Analysis Set. No formal statistical testing is planned.

All prior and concomitant medications (other than per-protocol study drugs) will be provided in a by-subject listing sorted by subject ID number and administration date in chronological order.

7.5. Electrocardiogram Results

7.5.1. Investigator Electrocardiogram Assessment

A shift table of the investigators' assessment of ECG results at each visit compared with baseline values will be presented by treatment group using the following categories: normal; abnormal (not clinically significant); abnormal (clinically significant); or missing. The number and percentage of subjects in each cross-classification group of the shift table will be presented. Subjects with a missing value at baseline or postbaseline will not be included in the denominator for percentage calculation.

No formal statistical testing is planned.

A by-subject listing for ECG assessment results will be provided by subject ID number and visit in chronological order

7.6. Other Safety Measures

A data listing will be provided for subjects who become pregnant during the study.

7.7. Changes From Protocol-Specified Safety Analyses

There are no deviations from the protocol-specified safety analyses.

8. PHARMACOKINETIC ANALYSES

Concentrations of filgotinib and its metabolite GS-829845 in plasma will be determined using validated bioanalytical assays. Plasma PK parameters of filgotinib and GS-829845, will be evaluated.

8.1. PK Analyses Related to Intensive PK Sampling

Steady-state PK over a 24 hour dosing interval will be determined in subjects in the PK Substudy Analysis Set.

8.1.1. Estimation of Pharmacokinetic Parameters

PK parameters will be estimated using Phoenix WinNonlin[®] software using standard noncompartmental methods. The linear/log trapezoidal rule will be used in conjunction with the appropriate noncompartmental model, with input values for dose level, dosing time, plasma concentration, and corresponding real-time values, based on drug dosing times whenever possible.

All predose sample times before time-zero will be converted to 0. Predose samples may also serve as the 24-hr post dose sample if appropriate.

For area under the curve (AUC), samples BLQ of the bioanalytical assays occurring prior to the achievement of the first quantifiable concentration will be assigned a concentration value of 0 to prevent overestimation of the initial AUC. Samples that are BLQ at all other time points will be treated as missing data in WinNonlin. The nominal time point for a key event or dosing interval () may be used to permit direct calculation of AUC over specific time intervals. The appropriateness of this approach will be assessed by the PK scientist on a profile-by-profile basis.

Pharmacokinetic parameters such as AUC_{τ} , t_z and $t_{1/2}$ are dependent on an accurate estimation of the terminal elimination phase of drug. The appropriateness of calculating these parameters will be evaluated upon inspection of PK data on a profile-by-profile basis by the PK scientist.

8.1.2. Pharmacokinetic Parameters

PK parameters will be generated for all subjects in the PK Substudy analysis set. The analytes presented in [Table 8-1](#) will be evaluated if data are available.

Table 8-1. Study Treatments and Associated Analytes

Treatment	Analyte
Filgotinib 200 mg	Filgotinib, GS-829845
Filgotinib 100 mg	Filgotinib, GS-829845

The analytes and parameters presented in [Table 8-2](#) will be used to evaluate the PK objectives of the study. The PK parameters to be estimated in this study are listed and defined in the Pharmacokinetic Abbreviations section.

Table 8-2. Pharmacokinetic Parameters for Each Analyte

Analyte	Parameters
Filgotinib	AUC _{last} , AUC _{tau} , C _{tau} , C _{max} , T _{max} , C _{last} , T _{last} , $t_{1/2}$, z , CL _{ss} /F, V _z /F, and $t_{1/2}$, if appropriate
GS-829845	AUC _{last} , AUC _{tau} , C _{tau} , C _{max} , T _{max} , C _{last} , T _{last} , $t_{1/2}$, z , and $t_{1/2}$, if appropriate

In addition, molar ratio of metabolite to parent exposure (AUC_{tau} and C_{max}) may be calculated for individual subjects and summarized by treatment. The GS-829845 to filgotinib ratio for AUC_{tau} will be calculated by dividing the AUC_{tau} (in h*nmol/L) of GS-829845 by the AUC_{tau} (in h*nmol/L) of filgotinib. The GS-829845 to filgotinib ratio for C_{max} will be calculated by dividing the C_{max} (in nmol/L) of GS-829845 by the C_{max} (in nmol/L) of filgotinib.

8.1.3. Statistical Analysis Methods

Individual subject concentration data and individual subject PK parameters for filgotinib and GS-829845 will be listed and summarized using descriptive statistics by treatment. Summary statistics (number of subjects [n], mean, SD, coefficient of variation [%CV], median, minimum, maximum, Q1, and Q3) will be presented for both individual subject concentration data by time point and treatment; and individual subject PK parameters by treatment. Moreover, the geometric mean, 95% CI, and the mean and SD of the natural log-transformed values will be presented for individual subject PK parameter data.

Individual concentration data listings and summaries will include all subjects with concentration data. The sample size for each time point will be based on the number of subjects with nonmissing concentration data at that time point. The number of subjects with concentration BLQ will be presented for each time point. For summary statistics, BLQ values will be treated as 0 at predose and one-half of the lower limits of quantitation (LLOQ) for postdose time points.

Individual PK parameter data listings and summaries will include all subjects for whom PK parameter(s) can be derived. The sample size for each PK parameter will be based on the number of subjects with nonmissing data for that PK parameter.

The following tables may be provided for each analyte by treatment:

- Individual subject concentration data and summary statistics
- Individual subject plasma PK parameters and summary statistics.

The following figures may be provided for each analyte by treatment (for PK substudy only):

- Individual subject concentration data versus time (on linear and semilogarithmic scales)
- Mean (\pm SD) concentration data versus time (on linear and semilogarithmic scales)
- Median (Q1, Q3) concentration data versus time (on linear and semilogarithmic scales)

Individual, mean, and median postdose concentration values that are LLOQ will not be displayed in the figures and remaining points connected.

The following listings may be provided:

- PK sampling details (and PK concentrations) by subject, including procedures, differences in scheduled and actual draw times, and sample age
- Individual data on determination of plasma half-life and corresponding regression correlation coefficient.

9. BIOMARKER ANALYSIS

A separate biomarker analysis plan (BAP) will document methods to analyze biomarker assessments.

10. REFERENCES

- Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. *Arthritis research & therapy* 2005;7 (4):R796-806.
- Bruynesteyn K, Boers M, Kostense P, van der Linden S, van der Heijde D. Deciding on Progression of Joint Damage in Paired Films of Individual Patients: Smallest Detectable Difference or Change. *Annals of the rheumatic diseases* 2005;64:179-82.
- Liu JT, Tzeng CS, Tsou HH. Establishing Non-Inferiority of a New Treatment in a Three-Arm Trial: Apply a Step-Down Hierarchical Model in a Papulopustular Acne Study and an Oral Prophylactic Antibiotics Study. *International Journal of Statistics in Med Research* 2014;3 (1):11-20.
- Ratitch B, O'Kelly M, Tosiello R. Missing data in clinical trials: from clinical assumptions to statistical analysis using pattern mixture models. *Pharm Stat* 2013;12 (6):337-47.
- Rubin DB. *Multiple Imputation for Nonresponse in Surveys*. New York, NY: John Wiley & Sons, Inc, 1987:
- Yuan Y. *Sensitivity Analysis in Multiple Imputation for Missing Data*. 2014:

11. SOFTWARE

SAS® Software Version 9.4. SAS Institute Inc., Cary, NC, USA.

nQuery Advisor(R) Version 4.0. Statistical Solutions, Cork, Ireland.

12. SAP REVISION

Revision Date (DD MMM YYYY)	Section	Summary of Revision	Reason for Revision
27 Nov 2018	Throughout the document	Editorial changes	Clarification
27 Nov 2018	Section 3.5	Update hierarchy list	Reflect endpoints importance
27 Nov 2018	Section 6.1	Estimands	Add definition of estimands
27 Nov 2018	Section 6.3.3	Non-inferiority sensitivity analysis	Add MI and TP analysis for non-inferiority tests
15 Jan 2018	Throughout the document	Editorial changes	Clarification

13. APPENDIX

Appendix 1. Lists of RA Medications

1) List of bDMARDs and Investigational bDMARDs (WHO Preferred Terms)

- ABATACEPT
- ADALIMUMAB
- CABIRALIZUMAB
- CERTOLIZUMAB
- CERTOLIZUMAB PEGOL
- CLAZAKIZUMAB
- DENOSUMAB
- ETANERCEPT
- GOLIMUMAB
- INFLIXIMAB
- INTERLEUKIN-2
- SIRUKUMAB
- TOCILIZUMAB

2) List of Oral Corticosteroids (WHO Preferred Terms)

- BETAMETHASONE
- BETAMETHASONE SODIUM PHOSPHATE
- CORTISONE
- DEXAMETHASONE
- DEXAMETHASONE PALMITATE
- DEXAMETHASONE PHOSPHATE
- DEXAMETHASONE SODIUM PHOSPHATE

- MEPREDNISONONE
- METHYLPREDNISOLONE
- METHYLPREDNISOLONE ACETATE
- METHYLPREDNISOLONE SODIUM SUCCINATE
- MOMETASONE FUROATE
- PREDNISOLONE
- PREDNISOLONE FARNESYLATE
- PREDNISONONE
- STEROIDS

3) List of Anti-malarials (WHO Preferred Terms)

- CHLOROQUINE
- CHLOROQUINE PHOSPHATE
- CHLOROQUINE SULFATE
- HYDROXYCHLOROQUINE
- HYDROXYCHLOROQUINE SULFATE

Appendix 2. Health Assessment Questionnaire Disability Index (HAQ-DI)

The HAQ-DI score is defined as the average of the scores of eight functional categories (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities), usually administered by the subject. Responses in each functional category are collected as 0 (without any difficulty) to 3 (unable to do a task in that area), with or without aids or devices.

The highest score for questions in each category (range 0 to 3) determines the score for the category, unless aids or devices are required. Dependence on equipment or physical assistance increases a lower score (ie, scores of 0 or 1) to the level of 2 to more accurately represent underlying disability. The eight category scores are averaged into an overall HAQ-DI score on a scale from 0 (no disability) to 3 (completely disabled) when 6 or more categories are non-missing. If more than 2 categories are missing, the HAQ-DI score is set to missing. The HAQ-DI can be treated as a continuous measure.

The HAQ-DI score using aids (and/or devices) is computed by taking the maximum score of the questions in each category (range: [0, 3]) and whether or not aids/devices are used (0 or 1):

$$A = \begin{aligned} & \max(\text{dressing \& grooming category questions, } 2 * \text{aids indicator}) + \\ & \max(\text{rising category questions, } 2 * \text{aids indicator}) + \\ & \max(\text{eating category questions, } 2 * \text{aids indicator}) + \\ & \max(\text{walking category questions, } 2 * \text{aids indicator}) + \\ & \max(\text{hygiene category questions, } 2 * \text{aids indicator}) + \\ & \max(\text{reach category questions, } 2 * \text{aids indicator}) + \\ & \max(\text{grip category questions, } 2 * \text{aids indicator}) + \\ & \max(\text{usual activities category questions, } 2 * \text{aids indicator}) \end{aligned}$$

$$\text{HAQ-DI} = A / (\text{total number of categories with at least 6 non-missing})$$

The following table shows the contribution of the 43 questions used to calculate the HAQ-DI:

HAQ-DI Category:	Category questions: At least 6 categories must have scores to compute the HAQ-DI.		HAQ-DI Category Score with Aids/Devices Calculation:
	Category Questions	Aids/Devices Indicators	
Dressing / Grooming	HAQ0101, HAQ0102 (DRESS, HAIR)	HAQ0114, HAQ0119 (DRSG, GROOM)	<p>Using each question with a scale of 0-3, calculate the category score as the maximum of the category questions.</p> <p>If the Aids/Devices indicator is “No”, no need to adjust the category score.</p> <p>If the Aids/Devices indicator is “Yes” and the category score is <2, then the category score with the Aids/Devices is set to 2.</p> <p>If the Aids/Devices indicator is “Yes” and the category score is 2, then the category score with Aids/Devices is the calculated category score without adjustment.</p> <p>For example: The Dressing/Grooming category score is 2 if subject answered 1 for both questions 1 and 2 and “Yes” for both question 14 and 19.</p> <p>In the HAQ-DI score calculation, questions on other device/aids will not be used.</p>
Arising	HAQ0103, HAQ0104 (STAND, BED)	HAQ0116, HAQ0120 (CHAIR, ARISING)	
Eating	HAQ0105, HAQ0106, HAQ0107 (MEAT, LIFT, MILK)	HAQ0115, HAQ0121 (UTENSIL, EAT)	
Walking	HAQ0108, HAQ0109 (WALK, STEPS)	HAQ0110, HAQ0111, HAQ0112, HAQ0113, HAQ0122 (CANE, WALKER, CRUTCH, WHEEL, WALKING)	
Hygiene	HAQ0123, HAQ0124, HAQ0125 (WASH, BATH, TOILET)	HAQ0134, HAQ0135, HAQ0137, HAQ0139, HAQ0142 (RAISEAT, BATHBAR, BATHSEAT, LONGBATH, HYGIENE)	
Reach	HAQ0126, HAQ0127 (REACH, BEND)	HAQ0138, HAQ0143 (LONGRCH, REACH)	
Grip	HAQ0128, HAQ0129, HAQ0130 (OPENCAR, JAR, FAUCET)	HAQ0136, HAQ0144 (JAROPEN, GRIP)	
Activity	HAQ0131, HAQ0132, HAQ0133 (SHOP, INCAR, CHORES)	HAQ0145 (ERRAND)	

Handling Missing Data: If no more than 2 categories have missing category scores, then the HAQ-DI is the mean of the non-missing category scores. Otherwise, the HAQ-DI score is set to missing.

If any of the category questions are missing, but the aids/device indicator is non-missing, the category score can still be computed. However, if all category questions and its aids/device indicators are missing, then the category score is considered missing.

Appendix 3. van der Heijde modified Total Sharp Score (mTSS)

1) Definition of mTSS

The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints in the feet, as shown below for the joints assessed for erosions.

Hands/Fingers MCP: Metacarpophalangeal joints I – V (n = 10)	Hands/Wrist: Multangular bones (trapezium & trapezoid) (n = 2)
Hands/Fingers PIP: Proximal interphalangeal joints II – V (n = 8)	Hands/Wrist: Scaphoid(Navicular) bones (n = 2)
Hands/Fingers IP (thumbs): Interphalangeal joints (n = 2)	Hands/Wrist: Lunate bones (n=2)
Hands/Fingers (thumbs): Proximal Metacarpal joints (n = 2)	Feet/Toes MTP: Metatarsophalangeal joints I – V (n = 10)
Hands/Wrist: Distal Radius (n = 2)	Feet/Toes IP (big toes): Interphalangeal joints (n = 2)
Hands/Wrist: Distal Ulna (n = 2)	

An erosion score of 0 to 5 is given to each joint in the hands and wrists, and a score of 0 to 10 is given to each joint in the feet. Each hand and wrist joint is scored, according to the surface area involved, from 0 to 5, with 5 indicating extensive loss of bone from more than one half of the articulating bone (0 indicates no erosion). Because each side of a foot joint is graded on this scale, the maximum erosion score for a foot joint is 10. Thus, the maximal erosion score is $(32*5) + (12*10) = 280$. A joint may not be evaluable due to surgery (ie, joint replacement) or may be radiographically insufficient for reading.

The joint space narrowing (JSN) score summarizes the severity of JSN in 30 joints of the hands/wrists and 12 joints of the feet, as shown below for the joints assessed for JSN.

Hand/Fingers MCP: Metacarpophalangeal joints I – V (n = 10)	Hand/Wrist: Capitate-scaphoid Joint (n = 2)
Hand/Fingers PIP: Proximal interphalangeal joints II – V (n = 8)	Hand/Wrist: Scaphoid-radius Joint (n=2)
Hand/Fingers CMC: Carpometacarpal joints III, IV, V (n = 6)	Foot/Toes MTP: Metatarsophalangeal joints (n = 10)
Hand/Wrist: Scaphoid-Trapezium Joint (n = 2)	Foot/Toes IP: Interphalangeal joints (n = 2)

Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, is scored from 0 to 4, with 0 indicating normal or no narrowing and 4 indicating complete loss of joint space, bony ankylosis, or luxation. Thus, the maximal JSN score is $(30*4) + (12*4) = 168$. A joint may not be evaluable due to subluxation, luxations, surgery (ie, joint replacement) or may be radiographically insufficient for reading.

The mTSS is defined as the erosion score plus the joint space narrowing score.

The maximum scores (adding up both hands/wrists and feet) are:

Radiography	Maximum score of hands/wrists	Maximum score of feet	Maximum score (add up hands/ wrists and feet)
Erosion score	32 joints * 5 = 160	12 joints * 10 = 120	280
JSN score	30 joints * 4 = 120	12 joints * 4 = 48	168
mTSS	280	168	448

2) Handling of Missing Joint Data

This section is focused on how to handle missing scores for individual joints during mTSS derivation.

If repeated X-ray was taken at screening, Week 12, Week 24 or early termination visit, the joint scores from the repeated X-ray will be set to missing if (repeated X-ray date - original X-ray date) > 28 days. At Week 52 the joint scores from the repeat X-ray will be set to missing if (repeated X-ray date - original X-ray date) > 42 days. If a joint was identified as surgically modified at screening, this joint will be set to be missing at all following visits.

Step 1 is to identify missing joint scores and impute values when applicable for each reader. The joints are divided into 8 segments. A segment is adequate when the total number of joints with nonmissing score is above the threshold as defined in the table below.

The change score of missing joints within an segment will be imputed based on the mean change scores of the available joints of that segment. After the missing joint change scores are imputed, the sum of joint change scores will be computed for each segment.

Segment	Total number of joints	Adequacy threshold
PIP Erosion	8	5
MCP and Thumb Erosion	12	7
Wrist Erosion	12	7
Foot Erosion	12	7
PIP JSN	8	5
MCP and Thumb JSN	10	6
Wrist JSN	12	7
Foot JSN	12	7

Step 2 is to identify missing timepoint and impute values when applicable for each reader.

The mTSS at baseline will be set to missing if any of the segments is inadequate. The mTSS at postbaseline visits will be set to missing if more than 3 segments are inadequate; otherwise imputation will be applied to imputed segments. The change score of the missing segments at a timepoint will be imputed based on the mean change scores of the available segments of that timepoint.

The erosion score and JSN score at baseline will be set to missing if any of the segments that contribute to derive either the erosion score or JSN score is inadequate, respectively. The erosion score and JSN score at postbaseline visits will be set to missing if more than 1 segment is inadequate, respectively; otherwise the change score of the missing segment will be imputed in the similar way as mTSS.

The missing joint scores at baseline will be imputed when all of the segments at baseline are adequate and the corresponding joints are scored at Week 24. If the corresponding segment at Week 24 is also adequate, the missing joint change scores at Week 24 will be imputed first using the method described before, and the missing joint score at baseline will be imputed as joint score at Week 24 minus the change in joint score. The mTSS at baseline will be the sum of the scores after imputation. The mTSS at postbaseline visits will be derived as change in mTSS plus baseline mTSS. The erosion score and JSN score at baseline and postbaseline visits will be derived in the similar way as mTSS.

Step 3 is to identify which reader pair will be used to derive final mTSS, erosion score and JSN score when an adjudicated read is present. The selection is made at Week 24 based on changes in mTSS as specified below and will be applied to all the visits.

- If both readers and adjudicator have change in mTSS available, the selected reader will be the one whose change in mTSS is closest to that of adjudicator. If the differences of change in mTSS comparing to adjudicator are the same for both readers, then both readers will be selected.
- If adjudicator's change in mTSS is available, but one of the readers' change in mTSS is missing, then the other reader will be selected.

Step 4 is to derive the final mTSS and final change in mTSS at a given timepoint. In the case of not adjudicated subjects the final mTSS will be the mean of the mTSS generated by the 2 readers. For the final change in mTSS, the change from baseline in mTSS will first be calculated for the 2 readers separately, and the final change score will be the mean of these two change scores. In the case of adjudicated subjects the final mTSS and final change in mTSS will be the mean of the mTSS and change in mTSS generated by the selected reader(s) at step 3 and the adjudicator respectively. The final erosion score, JSN score, and change in erosion and JSN score will be derived in the similar way as mTSS.

Appendix 4. Treatment Satisfaction Questionnaire for Medication (TSQM)

TSQM scale scores are computed by adding the items loading on each factor. The lowest possible score is subtracted from this composite score and divided by the greatest possible score minus the lowest possible score. This provides a transformed score between 0 and 1 that should be multiplied by 100. Note that only one item may be missing from each scale before the subscale should be considered invalid for that respondent.

EFFECTIVENESS:

$([\text{Sum}(\text{Item 1} + \text{Item 2} + \text{Item 3}) - 3] \text{ divided by } 18) * 100$

If one item is missing

$([\text{Sum}(\text{Item 1} + \text{Item 2} + \text{Item 3}) - 2] \text{ divided by } 12) * 100$

SIDE EFFECTS:

If Question 4 is answered 'No', then score = 100

Else,

$([\text{Sum}(\text{Item 5 to Item 8}) - 4] \text{ divided by } 16) * 100$

If one item is missing

$([\text{Sum}(\text{Item 5 to Item 8}) - 3] \text{ divided by } 12) * 100$

CONVENIENCE:

$([\text{Sum}(\text{Item 9 to Item 11}) - 3] \text{ divided by } 18) * 100$

If one item is missing

$([\text{Sum}(\text{Item 9 to Item 11}) - 2] \text{ divided by } 12) * 100$

GLOBAL SATISFACTION:

$([\text{Sum}(\text{Item 12 to Item 14}) - 3] \text{ divided by } 14) * 100$

If either Item 12 or 13 is missing

$([\text{Sum}(\text{Item 12 to Item 14}) - 2] \text{ divided by } 10) * 100$

If Item 14 is missing

$([\text{Sum}(\text{Item 12 and Item 13}) - 2] \text{ divided by } 8) * 100$

Appendix 5. Corticosteroids

The following table will be used for converting non-prednisone medications to prednisone equivalent:

Example: Subject is taking 8 mg of Methylprednisolone orally daily. To get the equivalent dose of prednisone: 8 mg Methylprednisolone = $(5 \times 8) / 4 = 10$ mg prednisone.

Corticosteroids Name	Equivalent Dose (mg) to 5 mg Prednisone
Betamethasone	0.75
Betamethasone Dipropionate	0.75
Betamethasone Sodium Phosphate	0.75
Cortisone	20
Dexamethasone	0.75
Dexamethasone Palmitate	0.75
Dexamethasone Phosphate	0.75
Dexamethasone Sodium Phosphate	0.75
Hydrocortisone	20
Meprednisone	4
Methylprednisolone	4
Methylprednisolone Acetate	4
Methylprednisolone Sodium Succinate	4
Prednisone	5
Prednisolone	5
Prednisolone Farnesylate	5
Prednisolone Sodium Succinate	5
Triamcinolone	4

Appendix 6. SAS Programming for Tipping Point Analysis for Binary Endpoint

The following **%tp_binary** macro generates multiple imputed data and a set of the shift parameters that adjust the imputed values will be examined.

```

/*-----*/
/*--- Delta-Adjusting Method for Tipping Point Analysis for Binary Endpoint ---*/
/*---
/*--- Generate imputed data set for specified shift parameters ---*/
/*--- data= input data set ---*/
/*--- smin= min shift parameter for active drug ---*/
/*--- smax= max shift parameter for active drug ---*/
/*--- sinc= increment of the shift parameter for active drug ---*/
/*--- pmin= min shift parameter for placebo drug ---*/
/*--- pmax= max shift parameter for placebo drug ---*/
/*--- pinc= increment of the shift parameter for placebo drug ---*/
/*--- trt= treatment group indicator ---*/
/*--- out= output imputed data set ---*/
/*-----*/

%macro tp_binary( data=, smin=, smax=, sinc=, pmin=, pmax=, pinc=, trt=, out=);
  data &out;
  set _null_;
  run;

  /*----- # of shift values -----*/
  %let ncase_pbo = %sysevalf( (&pmax-&pmin)/&pinc, ceil );

  %do pc=0 %to &ncase_pbo;

  %let pj= %sysevalf( &pmin + &pc * &pinc);

  /*----- # of shift values -----*/
  %let ncase= %sysevalf( (&smax-&smin)/&sinc, ceil );

  /*----- Imputed data for each shift -----*/
  %do jc=0 %to &ncase;

  %let sj= %sysevalf( &smin + &jc * &sinc);

  proc mi data=&data seed=14823 nimpute=20 out=outmi;
    var trt01pn strat1V strat2V strat3V ACR20;
    class trt01pn strat1V strat2V strat3V ACR20;
    monotone logistic (ACR20 / link=glogit);
    mnar adjust(ACR20 (event='1') / adjustobs=(trt01pn="&trt") shift= &sj)
      adjust(ACR20 (event='1') / adjustobs=(trt01pn='3') shift= &pj);
  run;

  data outmi;
  set outmi;
  Shift_Trts= &sj;
  Shift_Pbo= &pj;
  run;

  data &out;

```

```
        set &out outmi;  
        run;  
  
    %end;  
%end;  
%mend tp_binary;
```

Appendix 7. SAS Programming for Tipping Point Analysis for Continuous Endpoint

The following %tp_conti macro generates multiple imputed data sets and a set of the shift parameters that adjust the imputed values will be examined.

```

/*****
/*--- Modified Tipping Point Analysis from Yuan's method ---*/
/*---
/*--- Generate imputed data set for specified shift parameters ---*/
/*--- data= input data set ---*/
/*--- smin= min shift parameter for active drug ---*/
/*--- smax= max shift parameter for active drug ---*/
/*--- sinc= increment of the shift parameter for active drug ---*/
/*--- pmin= min shift parameter for placebo drug ---*/
/*--- pmax= max shift parameter for placebo drug ---*/
/*--- pinc= increment of the shift parameter for placebo drug ---*/
/*--- trt= treatment group indicator (eg, 1= filgotinib 200 mg) ---*/
/*--- out= output imputed data set ---*/
*****/

```

```

%macro tp_conti( data=, smin=, smax=, sinc=, pmin=, pmax=, pinc=, trt=, out=);
  data &out;
  set _null_;
  run;

```

```

  %let ncase_pbo = %sysevalf( (&pmax-&pmin)/&pinc, ceil );

```

```

  %do pc=0 %to &ncase_pbo;

```

```

    %let pj= %sysevalf( &pmin + &pc * &pinc);

```

```

    /*----- # of shift values -----*/
    %let ncase= %sysevalf( (&smax-&smin)/&sinc, ceil );

```

```

    /*----- Imputed data for each shift -----*/
    %do jc=0 %to &ncase;

```

```

      %let sj= %sysevalf( &smin + &jc * &sinc);

```

```

      proc mi data=&data out=all_mono nimpute=20 seed=123;
        var v_1 v_2 v_3 v_4 v_5 v_6 v_7 v_8 v_9;
        mcmc chain=multiple impute=monotone;
      run;

```

```

      proc sort data=all_mono; by _Imputation_ trt01pn; run;

```

```

      proc mi data=all_mono out=outmi seed=465 nimpute=1;
        by _Imputation_;
        var trt01pn strat1V strat2V strat3V v_1 v_2 v_3 v_4 v_5 v_6 v_7 v_8 v_9;
        class trt01pn strat1V strat2V strat3V;
        monotone regression;
        mnar adjust( v_5 / adjustobs=(trt01pn="&trt") shift=&sj)
              adjust( v_5 / adjustobs=(trt01pn='3') shift= &pj);

```

```
run;

data outmi;
    set outmi;
    Shift_Trtr= &sj;
    Shift_Pbo= &pj;
run;

data &out;
    set &out outmi;
run;
%end;
%mend tp_conti;
```

Appendix 8. Sample SAS Code for Analysis of Binary Endpoints

The following model statement will be used to construct the confidence interval for the binomial proportions described in Sections 6.2.3, 6.3.2 and 6.4.2:

```
proc freq data = test ;  
  by avisitn;  
  tables TRT01PN*aval_ / riskdiff (CORRECT);  
  output out = f200vp_ci RISKDIFF;  
  where TRT01PN = 1 | TRT01PN = 3;  
run;
```

where the confidence interval for the difference of two independent binomial proportions is constructed based on the normal approximation (ie, the Wald method) with continuity correction, to adjust for the difference between the normal approximation and the binomial distribution, which is a discrete distribution:

$$(\hat{p}_1 - \hat{p}_2) \pm \left(\frac{1}{2} \left(\frac{1}{n_1} + \frac{1}{n_2} \right) + z_{\alpha/2} \times \sqrt{\frac{\hat{p}_1(1 - \hat{p}_1)}{n_1} + \frac{\hat{p}_2(1 - \hat{p}_2)}{n_2}} \right)$$

and the confidence interval for the binomial proportions is constructed based on the normal approximation to the binomial distribution with continuity correction:

$$\hat{p}_1 \pm \left(\frac{1}{2n_1} + z_{\alpha/2} \times \sqrt{\frac{\hat{p}_1(1 - \hat{p}_1)}{n_1}} \right)$$